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Abstract
p90/CIP2A is a recently characterized oncoprotein which promotes cancer cell proliferation through the
inhibition of c-myc-associated PP2A phosphatase activity, from which it derived the name as cancerous
inhibitor of PP2A (CIP2A). Although p90/CIP2A has been found to be overexpressed in various cancer
types, from solid tumors to hematological malignancies, the function of this protein is still limited to its
ability to regulate the stability of c-myc. The recent study showing p90/CIP2A is able to regulate the
phosphorylation of protein kinase B (PKB) in response to the treatment of chemotherapy drugs implied
p90/CIP2A may have more functions. In order to investigate the function of p90/CIP2A in cancer
progression, we examined the expression level of p90/CIP2A in 72 lung cancer tissue specimen and 63
normal human lung tissues by immunohistochemistry, where results demonstrated that p90/CIP2A is
significantly overexpressed in lung cancer (84.7% in lung cancer v.s. 11.1% in normal lung tissue). In
addition, we also found that p90/CIP2A is overexpressed in primary lung cancer cell lines. Functional
analysis of the p90/CIP2A in lung cancer cell lines, either by knock-down or overexpression, confirmed
that p90/CIP2A is important for the cell proliferation.
To characterize the function of p90/CIP2A in tumor formation, we used three approaches to interrogate
the role of p90/CIP2A in lung cancer. First, we used phosphoproteome array to compare the
phosphorylation status of 72 key signaling molecules, and found that c-Jun N-terminal kinase (JNK) was
the molecules most significantly altered by the change of p90/CIP2A, which implied a possible target
utilized by p90/CIP2A to promote cell proliferation. Second, proteomic approach has been used to
identify the proteome change in response to the expression level change of p90/CIP2A. We identified 49
differentially expressed protein spots on 2D-gel in which 47 proteins are identified by mass
spectrometry. These proteins belong to different functional groups. A majority of the proteins are
associated with metabolism, signal transduction and transcription and translational control. Furthermore,
among these 47 differentially expressed proteins, 30 proteins have been well documented to be
v

associated with cancer, of which 12 proteins are up-regulated and 18 proteins are down-regulated after
knock-down of p90/CIP2A. To investigate whether these proteins are associated with any known
cancer-related pathway, differentially expressed proteins are searched against the database using
Pathway Studio bioinformatic software. The predicted network showed that four possible transcription
factors (c-myc, ESR-1, ETS-1 and CREB) may be involved in the regulation of the differentially
expressed proteins. Treatment with serum induced less phosphorylation of CREB in cells transduced
with p90/CIP2A shRNA than the cells tranduced with control shRNA. However, treatment with KCl and
forskolin did not have a significant difference between these two groups. Furthermore, we found that the
phosphorylation of the CREB upstream kinase AKT is also down-regulated, while other kinases p38 and
p90RSK is unaffected. This preliminary data implied that p90/CIP2A may target AKT-CREB pathway
to promote cell proliferation in a c-myc independent manner. At last, we applied gas chromatographymass spectrometry (GC/MS)-based metabolomic approach to identify the differential metabolites in
response to either the loss or overexpression of p90/CIP2A. Seventy-six metabolites were identified,
most of which were catergorized to nucleic acid metabolism, carbohydrate metabolism and fatty acid
metabolism. By using Significant Analysis of Microarray (SAM) and independent component analysis
(ICA), we identified three metabolite: D-glucose, L-proline and 1,2,3-propanoic acid, which can be the
biomarkers to differentiate the overexpression of p90/CIP2A to the loss of p90/CIP2A. Furthermore, we
found that the depletion of p90/CIP2A would cause the accumulation of glucose inside the cell, while
the overexpression would promote glucose utilization. The quantification of glucose in a dynamic way
showed that p90/CIP2A does not have an effect on glucose uptake, instead, it regulates the glucose
metabolism through the regulation of hexokinase activity. Our data strongly suggested that the role of
p90/CIP2A in promoting cell proliferation is not only replied on c-myc, but also in a c-myc-independent
manner.
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Chapter 1: General introduction
1.1

Lung cancer

Lung cancer is a type of cancer which usually forms in the result of uncontrolled cell growth in
the tissue of the lung. Lung cancer has been recognized as one of the most common causes of cancerrelated death in both men and women throughout the world [1]. It is the second leading cancer “killer”
in the United States, accounting for more deaths than breast cancer, prostate cancer and colon cancer
combined [1]. According to the latest data from American Cancer Society, there would be about 222,520
new cases of lung cancer (both small cell and non-small cell) in the United States in 2010 and about 157,
300 people would die from it the same year [1]. The average lifetime chance that a man will develop
lung cancer is 1 in 13. For a woman it is 1 in 16. About 4 out of 10 people with lung cancer will still be
living one year after finding out they have lung cancer[1].

According to the histological type, lung cancer can be classified into small cell lung cancer
(SCLC) and non small cell lung cancer (NSCLC). Compared to NSCLC, SCLC is less common and
accounts for 15~20% of all the lung cancer cases. Most of SCLC cases occur in the larger airways
including primary and secondary brochi [2]. SCLC cells are fast-growing cells and thus become quite
large under microscope [2]. The SCLC cells normally contain dense neurosecretory granules containing
hormones like neuroendorcrine, which give this tumor an endocrine/paraneoplastic syndrome
association [3]. SCLC is sensitive to the treatment of chemotherapy and radiation, it always have
metastasized at presentation and therefore carries a worse prognosis [2] . This type of lung cancer is
strongly associated with smoking [4]. The stage of SCLC can be dichotomously divided into limited and
extensive stage disease.
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The NSCLC has three main types: squamous cell lung carcinoma, adenocarcinoma and large cell
lung carcinoma. These three types of cancer are grouped together simply because they behave similarity;
share similar prognosis and management [2]. Squamous cell lung carcinoma, which usually starts near a
central bronchus, account for 25% of lung cancers [4, 5]. A hollow cavity and associated necrosis are
commonly found at the center of the tumor [6]. Well-differentiated squamous cell lung cancers often
grow more slowly than other cancer types [7].

Adenocarcinoma accounts for 40% of non-small cell lung cancers [6]. It usually originates in
peripheral lung tissue. Most cases of adenocarcinoma are associated with smoking; however, among
people who have never smoked ("never-smokers"), adenocarcinoma is the most common form of lung
cancer [6]. Lung cancers are highly heterogeneous malignancies were containing more than one subtype
is very common [3].

1.2

Pathogenesis of lung cancer

Although the oncogenesis of lung cancer is still poorly understood, like many other cancers, it is
believed that lung cancer is initiated by activation of oncogenes and inactivation of tumor suppressor
genes [8].

K-ras (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is a protein with GTPase function
that belongs to the Ras gene family.

It is an early player for signal transduction by acting as an on/off

molecular switch [9]. Upon growth factor activation (e.g. EGF), wild type K-ras can bind to GTP and
convert it to GDP through its intrinsic enzyme activity [10, 11]. After that, the K-ras will be turned off
and leave the substrate. Unfortunately, the mutation of this gene, for example the K-ras G12D mutant
gene, can generate constitutively active form of K-ras, which will keep converting GTP to GDP[11].
Thus, this K-ras mutation results in the over propagation of downstream pathways such as c-Raf and
2

PI3K pathway leading to tumor growth[9]. The mutations of this gene are found in 10–30% of lung
adenocarcinomas [10] .

EGFR (epidermal growth factor receptor) is a cell-surface protein involved in a wide variety of
cell processes such as cell proliferation, apoptosis, angiogenesis and cell invasion by binding to the
mitogenic factors like EGF [9]. Upon ligand binding, EGFR is activated to phosphorylate down-stream
molecules through its tyrosine kinase activity. Like K-ras, mutations and amplification of this gene are
also very common in non-small cell lung cancer [10]. The mutation of this gene is always associated
with its tyrosine kinase activity. For example, the mutation of T570 and L858 within the kinase domain
is commonly found in non small-cell lung cancer patients [11, 12]. The recently developed EGFR
inhibitor drug, Gefitinib (Iressa), has been introduced to treat patients who are carrying EGFR mutation
[9].

p53, which is encoded by TP53 gene in human genome, is a frequently mutated gene in lung
cancer. The deletion of this gene or mutation at DNA binding domain sites is very common in lung
cancer [13]. p53 is a tumor surpressor gene and exert its anti-tumor function by regulating the
transcription of a variety of pro-apoptotic genes like p16, p21 and p27, which will induce cell growth
arrest, cellular senescence or apoptosis [14]. Of notice, some mutant p53, like p53 R175H and R275H,
have dominant effects on the wild type p53. They can also promote cell invasion and metastasis [15].

LKB1 (STKE11) is a kinase which is frequently mutated in non small cell lung cancer [16]. This
protein was initially identified as an energy homeostasis regulating kinase [17]. The subsequent studies
showed that LKB1 exerts its anti-tumor activity by activating AMPK and AMPK-related kinases to
inhibit tumor cell growth when energy and nutrients become scarce. Another important function of
LKB1 is in cell polarity. LKB1 is important for epithelial cell polarization and prevention of tumor cell
expansion, whereas the loss of this protein in cancer cells will lead to unorganized cell structure and
3

tumor growth [17]. The mutations of this gene are also found in other cancers like cervical cancer,
testicular cancer, breast cancer, pancreatic cancer and skin cancer [18].

Other genes that are often mutated or amplified are c-MET, NKX2-1, LKB1, PIK3CA and BRAF
[19]. Several genetic polymorphisms are associated with lung cancer. These include polymorphisms in
genes coding for interleukin-1, cytochrom P450, pro-apoptotic proteins like caspase-8, and DNA repair
molecules such as XRCC1[13, 20, 21 22] (Table 1).

4

Table 1. Genetic abnormalities specific in the lung to non-small-cell lung cancer and small-cell
lung cancer (Herbst R. et. al NEJM, 2008)

5

1.3

Protein phosphatase 2A and cancer
Protein phosphatase 2A (PP2A), a large family of heterotrimeric serine-threonine

phosphatases, account for the majority of serine-threonine phosphatase activity in eukaryotic cells [23].
The PP2A holoenzyme consists of a structural A subunit, known as PR65 or PPP2R1, a catalytic C
subunit, known as PP2Ac or PPP2C and a regulatory B subunits. The A subunit provides a scaffold that
allows the the binding of C subunit and B subunit, which regulate the substrate specificity and the
localization of the PP2A complex. In mammalian cells, the A subunit and C subunits are encoded by
two distinct genes which produce two isoforms for each unit, Aα and Aβ

and Cα and Cβ, respectively.

So far, four families of B subunits have been reported: B/B55/PR55/PPP2R2 [24-27],
B′/B56/PR61/PPP2R5 [28-30], B″/PR72/PPP2R3 [31-34] and B″′/PR93/SG2NA/PR110/Striatin [35]
(Fig. 2).
The tumor suppressor activity of PP2A was firstly resulted from the discovery of okadaic acid, a
selective but not specific PP2A inhibitor (inhibit PP2A at picomolar concentration and inhibit both of
PP2A and PP1 at higher concentration), which can promote tumor formation in mouse model [36].
Therefore, it is believed that inhibition of PP2A is critical for human cell transformation which validated
by the fact that small T antigens from two high risk viruses, SV40 and polyoma can target PP2A and this
is essential for the cell transformation. When the mutations were introduced to abolish the interaction
between ST and PP2A, the normal cell cannot be transformed [36].
Since the PP2A holoenzyme is a combination of A, B and C subunits, recent studies have been focusing
on how the different subunits contribute to tumor suppression. A pioneering study by knocking-down of
the B56 family, Chen et al. have developed an assay system by using the non-tumorigenic HEK-TRV
cell line which has been immortalized with hTERT, large T antigen and H-ras. The advantage of this
system is based on the fact that the inhibition of PP2A in this cell line can result in cell transformation.
They found that the down-regulation of B56 γ in

this cell line led to cell transformation, which is
6

mimicking the expression of small T- antigen [37]. Although A alpha and A beta have low frequency of
somatic mutation in cancers, the loss of either of these two genes will enhance the cell transformation
[36-38]. The mutations of these two genes can abolish the PP2A complex due to the inability to form the
A-C heterodimer [39]. Although the mechanism of how PP2A exerts its tumor suppressor function is
poorly understood, the A alpha subunits can form complex with B56 gamma to control the
phosphorylation of AKT [36, 40, 41]. The depletion of either A alpha or B56 gamma will induce the
hyperphosphorylation of AKT, indicating the necessary role of active AKT in cell transformation [40,
41]. In addition, the PP2A A alpha-B56 gamma complex can also regulate the stability of p53, another
important tumor suppressor [42]. MDM2 is an E3 ligase for p53 by phosphorylating p53 at Thr55,
which is a signal for proteasome-mediated protein degradation. The dephosphorylation of p53 at Thr55
by PP2A is essential for its anti-tumor activity [42]. The mutation of A beta subunits was recently found
to exert its tumor suppressor function by regulating the phosphorylation of Ral A which is an important
oncoprotein at the downstream molecule of the Ras signaling pathway [43]. The mutation of A beta was
found to be missing in lung cancer specimen and several lung cancer cell lines [37]. The introduction of
mutant A beta into immortalized cell line will result in cell transformation. The C subunits do not have
tumor suppressor activity [44]. The B56 family subunits can regulate the stability of beta-catenin

and

B56 alpha can regulate the stability of c-myc by dephosphorylating c-myc at Serine 62, which is
phosphorylated by ERK and is essential for its stability[45][46]. The desphorylation at this site will
result in the subsequent phosphorylation of c-myc by GSK-3β [46]. These two events will result in the
proteosome-mediate c-myc degradation [47].

7

Figure 1. Structure of PP2A holoenzyme. PP2A is a heterotrimeric complex consisting of a scanffold
subunit (Aα or Aβ), catalytic subunit (Cα or Cβ) and a regulatory subunit (B, B’, B’’ or B”’), which
regulate the substrate specificity and subcellular localization. (Westermarck J & Hahn WC. Trends Mol
Med ,2008)
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1.4

PP2A inhibitors
Okadaic acid is the first chemical shown to inhibit PP2A phosphatase activity [36] (Fig. 2A). The

essential role of oncoprotein, small T antigen of SV40 virus and polyma virus, in cell transformation is
heavily replied on its ability to inhibit PP2A phosphatase activity [48]. Small T antigen inhibits PP2A
activity by replacing B subunits and preventing the formation of active PP2A holoenzyme [48].
Unfortunately, no endogenous PP2A inhibitor was identified until the discovery of I1PP2 and I2PP2A
from bovine kidney cell lysates [49]. These two inhibitors are heat-stable and inhibit PP2A phosphatase
in a non competitive manner [49].

Although the function of both of I1PP2A and I2PP2A is not fully

understood, the overexpression of I2PP2A/SET has been observed in several different tumor types [36].
As one of the cancer-related pathways, mitogen activated protein kinase (MAPK) are important targets
for PP2A. The inhibition of PP2A by okadaic acid or ectopic expression of small T antigen can promote
the activation of MAPK pathway through phorsphorylation regulation. For example, the overexpression
of small T antigen or I2PP2A can induce the phosphoryaltion of c-Jun at S63 and T73, which mediate
the transcriptional activity of oncoprotein AP-1 [50-52]. However, the question that remains to be
answered, is whether I2PP2A can directly or indirectly regulate these phosphorylation events. Besides
that, the overexpression of I2PP2A in Hela cell can inhibit death-receptor-mediated apoptosis through
activation of MEK-ERK-MAPK pathway [53].
In addition to its function on PP2A phosphatase activity inhibition, I2PP2A/SET can also form fusion
proteins with Nup214, and SET-Nup214, which are overexpressed in chronic myelogenous leukemia
(CML) [54]. In this study, it is also found that the overexpression of this fusion protein is essential in
CML for the oncogenic activity of BCR-ABL kinase. Downregulation of this fusion protein via
sequence-specific siRNA can reduce the stability of BCR-ABL kinase by promoting its proteolytic
degradation. In addition to that, several signaling pathways involved in CML pathogenesis got
interrupted. Interestingly, the overexpression of I2PP2A/SET can also be induced by the fusion protein
9

BCR-ABL kinase since the inhibition of BCR-ABL by Imatinib can markedly inhibit I2PP2A/SET
expression [36, 54] (Fig 2B).
A recent study showed that the re-activation of PP2A by forced expression of PP2A C subunit or
by Imatinib can result in the inhibition of c-myc expression by dephosphorylation of STAT5, ERK,
AKT, BAD, Jak2 and pRB. It has been shown that the proteolytic degradation of BCR-ABL induced by
the loss of I2PP2A/SET was highly dependent on tyrosine phosphatase SHP-1. Although the underlying
mechanism for the SHP-1 inactivation by overexpression of I2PP2A/SET remains unknown, it is
possible that the PP2A may be able to directly regulate the phosphorylation status of SHP-1. The
overexpression of I2PP2A/SET can greatly increase the colony-forming growth in soft agar and cell
proliferation. These resuls showed that I2PP2A/SET can promote CML tumorigenesis by increasing the
stability of the oncogene BCR-ABL through inhibition of PP2A phosphatase activity [54].

10

A.

B.

Figure 2. (A) Chemical structure of PP1 and PP2A inhibitor (Wikipeida, the free encyclopedia). (B)
Signaling pathway targeted by PP2A inhibitor I2PP2A. Oncoprotein BCR-Abl is negatively regulated
by SHP-1 phosphatase, which is positively regulated PP2A phosphatase. The BCR-Abl can stimulate the
expression of I2PP2A/SET, which in turn inhibit PP2A phosphatase activity and thus increase the BCRabl activity. Although I2PP2A can increase the phosphorylation of MEK1/2 and JNK-c-Jun, the direct
targets of I2PP2A are unknown. (Westermarck J & Hahn WC. Trends Mol Med ,2008) .
11

1.5 90-kD tumor associated autoantigen or cancerous inhibitor of PP2A (p90/CIP2A)
c-myc is an important transcriptional factor in both normal cell and malignant cell growth [55].
This protein is subject to tight regulation through several different mechanisms of both transcriptional
and post-transcriptional [55]. Although the overexpression of this protein in tumors always resulted from
gene amplification or translocation, some evidence showed the mRNA level is not correlated with
protein level, which implied the post-transcriptional level is also of great importantce in regulating its
stability [56-60]. In fact, the c-myc protein has a half-life with only 30 mins under normal conditions
[61]. The stability of this protein is regulated by two phosphorylation events [47]. The phosphorylation
of Serine 62 by ERK can increase its stability and function. The dephosphorylation at this site by PP2A
will result in the phosphorylation at T58 by GSK 3beta, which is a critical step for c-myc proteolytic
degradation. The mutation of Serine 62 to Alanine will result in the instability of c-myc, but the
mutation of T58 to A will result in the accumulation of c-myc and can enhance cell transformation [47].
p90/CIP2A is a novel PP2A inhibitor which can extend the half life of c-myc [62] (Fig. 3). This
protein was initially identified as a tumor-associated autoantigen during the screening of biomarker in
gastric cancer. This protein was originally named p90 autoantigen due to its migration band at
approximately 90kD on SDS-PAGE gel [63]. The function of this protein at that time was unknown.
Recently, this protein was found to be co-precipitated with PP2A A alpha subunit. The global
microarray analysis revealed it can regulate the stability of the oncoprotein c-myc. The underlying
mechanism of this regulation is based on the ability of p90/CIP2A to inhibit the phosphatase activity of
PP2A. Therefore, they proposed to call cancerous inhibitor of PP2A (CIP2A). The knock-down of this
protein in Hela cell result in decreased cell proliferation, clonogenic ability and anchorage-independent
growth. The injection of the cells with depleted p90/CIP2A into nude mice will decrease the in vivo
tumor formation. This protein can also substitute ST for cell transformation in the cell line which was
immortalized by hTRET, LT and H-ras [62].
12

Later, several other groups confirmed the importance of p90/CIP2A in tumor formation in different
cancer types like breast cancer, prostate cancer, gastric cancer, non small cell lung cancer, oral
carcinoma, esophageal squamous cell carcinoma and chronic myeloid leukemia [64-70]. In addition, two
groups also showed that p90/CIP2A can confer drug-resistance by regulating the phosphorylation of
AKT in hepatocellular carcinoma and breast cancer [71, 72]. However, how this protein contributes to
cancer progression besides its role in regulating the stability of c-myc is still poorly understood.
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Figure 3. Proposed mechanism of p90/CIP2A-meidated c-myc stability. C-myc stability is
regulated by dephosphorylation of S62 by PP2A and phosphorylation of T58 by GSK3β. The synergism
of PP2A and GSK3β can lead to the proteasome degreadation of c-myc. However, p90/CIP2A is able to
recognize the motif including the S62, which shield the dephosphorylation by PP2A, and extend the
stability of c-myc. (Westermarck J & Hahn WC. Trends Mol Med ,2008)
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1.6 Other endogenous PP2A inhibitor proteins
In addition to I1PP2A, I2PP2A/SET and p90/CIP2A, some other endogenous proteins inhibiting
PP2A activity in cancer cells have been identified.

PP2A C methylesterase protein phosphatase

methylesterase-1 (PME-1) is able to demthylate PP2A catalytic domain at its C-terminal leucine 307 by
binding to the inactive form of catalytic domain of PP2A [73, 74]. Another endogenous PP2A inhibitor
is type 2A-interacting protein (TIP), which was shown to be expressed in human cancer cells and to
interact with the PP2A holoenzyme in HEK-293 cells [75]. An in vitro study showed that this protein
can directly inhibit PP2A phosphatase activity. TIP depletion resulted in a significant decrease in the
phosphorylation of newly identified 32 kD target protein substrate of ataxia-telangiectasia mutated
(ATM)/ATM- and Rad3-related (ATR) kinases [75].

1.7 Metabolism and cancer
Cancer is a type of diseases with uncontrolled cell growth, which lost the checkpoint of cell
proliferation of normal cells [76]. To support the rapid cell proliferation, the cancer cells must make
fundamental changes in order to meet the requirement for increased nutrient uptake and energy
production. The link between metabolism and cancer was initially observed by a German physiologist,
Otto Warburg. In the early 1920s, he proposed that the malignant growth of cancer cells was caused by
energy production through non-oxidative breaking down of glucose to produce NADH, even in the
presence of ample oxygen, which is known as glycolysis. In contrast to cancerous cells, normal cells
promote energy production through mitochondrial oxidation, which breaks down pyruvate, the end
product of glycosis [77]. The distinct ways used by glucose to produce energy between cancer cells and
normal cells lead to the development of positron emission tomography (18-FDG PET), which monitors
malignant growth by measuring glucose uptake [78].
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Otto Warburg theorized that mitochondria deficiency was the primary cause of cancer. Yet, the
understanding of cancer genetic lesions like oncogene activation or inactivation of tumor suppressors
opposed the idea that genetic change reprogrammed the metabolic pathway to favor glycolysis rather
than oxidative phosphorylation in the mitochondria, since the mitochondria remains normal in many
cancer cells [79, 80]. Glucose is not only the substrates needed for energy production, but also the major
carbon source for the synthesis of macromolecules; thus a critical nutrient in anabolic metabolism.
Compared to mitochondrial oxidative phosphorylation, which gives rise to 36 ATP/ mol glucose,
glycoslysis can only generate as low as 2 ATP/ mol glucose. This inefficient production of energy seems
paradoxical to the high demands of energy in cancer cells [81]. Glycoslysis actually has at least two
advantages over oxidative phosphorylation. First, glycolysis can produce ATP faster than oxidative
phosphorylation when glucose is present in excess [78]. Up-regulation of glucose transporter 1 (Glu1)
has been found in many different types of cancer. The increased import of glucose into cancer cells is
thus providing sufficient nutrients for anabolism process. Another important feature of glycolysis are the
intermediate products that are important for cell growth. For example, glucose can be metabolized in
either oxidative or non-oxidative way of pentose phosphate pathway (PPP). The intermediate product,
ribose-5-phosphate, is an important molecule for nucleotide synthesis. NADH can also be produced by
PPP pathway and used for nucleotide and fatty acid biosynthesis [82-84].
The reprogramming of metabolic signaling networks is considered as a hallmark of cancer [85]. More
and more evidence has shown that almost every oncogene has downstream effectors to be associated
with cancer metabolism. Frequently mutated oncogens like c-myc, Ras, Src and AKT can stimulate the
anabolism in transformed cells and thus constitute major metabolic pathways in cancer cells [79]. C-myc
is a proto-oncogens regulating nearly 15% of genes in the human genome [86]. C-myc is activated by
growth factors and modulates cell proliferation and cell-cycle process in normal cells. However,
deregulated c-myc expression due to genetic amplification is frequently observed in cancer [87], which
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resulted in the over-expression of its regulated genes. Many of the c-myc targeted genes are metabolism
genes, such as LDH-A, which is an enzyme that converts pyruvate into lactate and recovers the NAD+
to maintain glycolysis to support the tumor growth [88]. Recent evidence has shown that c-myc
promotes cell proliferation by enhancing glycolysis, but also participates in glutamine metabolism,
known as glutaminolysis [89, 90]. Another important molecules is phosphotydilinositol 3 kinase (PI3K),
which is a lipid kinase, that phosphorylates the 3 hydroxyl group of inositol and thus regulate the level
of phosphorylated phosphotydilinnositol (PIP3) at the plasma membrane in response to growth factor
stimulation [91-93]. Activation of PI3K will lead to the activation of downstream molecule AKT, which
plays central roles in cell proliferation and cell growth by phosphorylating a wide variety of substrates.
AKT activation can stimulate cell growth by increasing enzymatic activity of glycolytic enzymes like
hexokinases and phosphofructose [94, 95]. AKT can also increase gene expression related to nutrient
transporters like amino acid transporter and glucose transporter [96]. In addition, AKT can also regulate
other proliferation promoting molecules like mammalian target of rapamycin (mTOR).
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1.8 Project hypothesis and specific aims
Our hypothesis is that overexpression of p90/CIP2A in lung cancer cell could promote cell proliferation
by different ways, simply classified as c-myc-dependent and c-myc-independent. To find the mechanism
of the p90/CIP2A-associated cell proliferation, we have the following specific aims:
Specific aim 1: Evaluate the expression of p90/CIP2A in lung cancer specimen and lung cancer cell
lines.
In this specific aim, we will use immunohistochemistry (IHC) and western-blot to analyze the
expression level of p90/CIP2A in tumor tissue array and primary lung cancer cell lines. Results obtained
from this specific aim could allow us to know whether p90/CIP2A is associated with lung cancer
formation.
Specific aim 2: Functional analysis of p90/CIP2A-induced proteome change.
In this specific aim, we intend to use proteomic approach to identify differentially expressed protein
between the wild-type cancer cell line and the p90/CIP2A-deficient cells. The loss of certain proteins
may result in the change of the expression of its regulated proteins, which can be detected by proteomic
approach. Further analysis of these proteins through bioinformatic tools may uncover novel functions.
Specific aim 3: Identification of novel p90/CIP2A targets by phosphoproteomics.
In this specific aim, we will adopt phosphoproteomic approach to identify novel targets of p90/CIP2A
by examining the phosphorylation of key signaling molecules when p90/CIP2A is overexpressed.
Identified targets will be reconfirmed with phosphorylation-specific antibody. This information will help
us to establish the link between p90/CIP2A with other known signaling molecules and thus have
implication for novel function.
Specific aim 4: Analysis of p90/CIP2A in cancer metabolism by metabolomic analysis.
Serving as an oncoprotein in human cancer, p90/CIP2A significantly increases cell proliferation, a
phenotype linked cancer metabolism. By systematic profiling of the metabolites in the context of
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depleted or overexpressed p90/CIP2A, we will be able to identify p90/CIP2A-associated metabolic
pathway.
1.9 Significance
Understanding the underlying mechanisms of tumorigenesis and cancer progression is the key to
develop efficient drug targets for cancer treatments. Genetic lesions have been considered as the key
players during cellular transformation and cancer progression. However, directly targeting these
molecules is sometimes disappointed in practice due to the complicated inter-relationship between
cancer cells and their microenvironment. Thus, the choice of the optimal drug targets is of great
importance. We found that p90/CIP2A can be a potential biomarker for cancer detection and is a
possible drug target based on the following reasons. First, p90/CIP2A is overexpressed in lung cancer
tissue while only a few cases of normal human tissue are p90/CIP2A positive. In addition, the high
frequency of autoantibody against p90/CIP2A in lung cancer patients makes this protein as a potential
serological biomarker for lung cancer detection. Second, p90/CIP2A is tightly regulated by
development. The expression of this protein is silenced in normal adult tissues and thus targeting this
protein may have less off-targets. At last, the complexity of cancer makes it difficult to cure by targeting
individual molecules. The data presented in this dissertation can provide the researcher the rationale for
the role of how p90/CIP2A affects the signaling in cancer cells, which may be important for
combinatorial use of drugs to treat cancer. In addition, the inhibition of p90/CIP2A can restore the PP2A
phosphatase activity which leads to the impediment of cancer cell growth.
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Chapter 2: p90/CIP2A is a tumor-associated autoantigen in human lung cancer
2.1

Introduction
Lung cancer causes most cancer-related death both in men and women throughout the world.

Based on the size of cancer cells examined under microscopy, lung cancer can be classified to small cell
lung cancer (SCLC) and non small cell lung cancer (NSCLC), which have different cell origins, genetic
lesions and therefore respond differently to treatments [97]. However, NSCLC is more common than
SCLC, which account for 85% cases of lung cancer diagnosed. The five year survival rate of lung cancer
is as low as 15% [98]. Therefore, early detection of this disease allows the patients to receive
appropriate treatment with more options and less invasive surgery, which leads to the increased fiveyear survival rate [98]. Unfortunately, one challenging issue for the early detection of lung cancer is the
disease-associated symptoms, which can be hardly felt by the patients at the early stage. Therefore, lung
cancer is usually diagnosed at late stage when the cancer cells are distantly localized. Therefore, the
development of reliable biomarkers for early detection of lung cancer is a novel field since there is no
currently approved screening test for lung cancer detection [98].
Blood proteins have always been attractive targets for biomarker identification due to their
change of expression with the progression of diseases [99, 100] . Studies of autoimmune diseases have
provided abundant evidence suggesting that autoantibodies are antigen-driven responses that can be
viewed as reporters from the immune system, which reveal the identity of antigens that might be playing
roles in the pathophysiology of the disease process [100, 101]. The highly specific autoantibody
response in systemic autoimmune disease generally predicts the biologic phenotype of the disease,
making autoantibodies clinically valuable and diagnostically useful. Of notice, most of the autoantigens
targeted by host’s immune system were identified as the proteins which play important roles in cell
transformation and cancer progression like mutant p53, K-ras, insulin-growth factor II mRNA binding
protein family (IMPs), c-myc, p90/CIP2A, p16, p21, cyclin A, B and E [101, 102]. Therefore the
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identification of tumor-associated autoantigen is a way of understanding the antigens that are recognized
by the host’s immune system during cellular transformation and cancer progression. It is also a way to
identify the proteins that are aberrantly regulated during the transformation of normal cell to cancerous
cell.
p90/CIP2A is a tumor-associated autoantigen that was initially identified in gastric patients
which has unknown functions due to it lacks the homology to any other proteins [63]. It was later shown
that this protein is overexpressed in many different types of cancer and promotes cancer cell
proliferation by inhibiting c-myc-associated protein phosphatase 2A (PP2A) phosphatase activity, which
resulted in the extended half-life of c-myc oncoprotein [62]. Furthermore, the analysis of other known
PP2A substrates like MEK (mitogen-activated protein kinase-kinase) and MDM2 were unaffected,
which implied the target selectivity of p90/CIP2A in cancer cells [62]. In addition, the recent studies
showed that p90/CIP2A is able to regulate the phosphorylation of another substrate: protein kinase B
(PKB/AKT). p90/CIP2A is positively regulating AKT phosphorylation in hepatocellular carcinoma and
confer cancer cell with the resistance to bortezomib, an anti-cancer drug [71, 103]. However, whether
p90/CIP2A has other functions is still poorly understood.
In search of novel tumor-associated autoantigen in lung cancer patients, we established if
p90/CIP2A can also elicit autoimmune response in lung cancer patients. Further analysis demonstrated
that p90/CIP2A is highly expressed in lung cancer specimen but with very low expression in normal
human lung tissue. In addition, p90/CIP2A is also expressed in different lung cancer cell lines. These
data again validated the possibility of using p90/CIP2A as a biomarker for early cancer detection. In
addition, the functional analysis of p90/CIP2A in lung cancer cell lines showed the participation of
p90/CIP2A in cell proliferation through a novel mechanism, which regulated the JNK-c-Jun MAPK
pathway.
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2.2

Materials and methods

Cell culture. The non-small cell lung cancer cell lines, A549, NCI-H838, NCI-H1299 and NCI-H460
and two small cell lung cancer cell lines, H69 and H146 were purchased from Amercian tissue
collection center (ATCC). All of the cell lines, except A549, were cultured in RPMI-1640 medium
(Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (FBS) (Invitrogen) at 37oC with 5% CO2.
A549 is cultured with the same conditions as for other cell lines, except that it is cultured in F12K
medium (Invitrogen).
Serum sample. In this study, sera from 207 patients with lung cancer and 82 normal human sera were
obtained from the serum bank in the investigator’s (Zhang) laboratory at The University of Texas at El
Paso (UTEP), which were originally provided by a collaborator in Sun Yat-sen University, Guangzhou,
China. Normal human sera were collected from adult individuals who had no obvious evidence of
hepatic diseases during annual health examinations. Histopathological staging of liver fibrosis was
defined using METAVIR scoring system. All lung cancer patients were diagnosed according to the
criteria described in a previous study [104]. This study was approved by the Institutional Review Board
of The University of Texas at El Paso and collaborating institutions.

ELISA. Recombinant GST-p90/CIP2A fusion protein was purified using GST glutathione beads. The
protein purity was >95% by SDS-PAGE. Proteins were diluted in PBS to a final concentration of 0.5
μg/mL for coating polystyrene 96-well microtiter plates (Dynatech Laboratories, Alexandria, VA). A
volume of 200 μL of each human serum samples at 1:200 dilutions was added to the antigen-coated
wells and incubated for 1.5 h at RT. Horseradish peroxidase-conjugated goat antihuman IgG (Caltag
Laboratories, San Francisco, CA) at 1:5,000 dilution and the substrate 2,2′-azinobis (3ethylbenzthiazoline-6-sulfonic acid) (Boehringer Mannheim GmbH, Mannheim, Germany) were used as
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detecting reagents. Each sample was tested in duplicate, and the average OD at 405 nm was used for
data analysis. The cutoff value designating positive reaction was the mean optical density (OD) of 82
normal human sera plus 3 standard deviations (SD). The detailed protocol of ELISA was used as
described.

Tumor tissue array, H&E staining and immunohistochemistry (IHC). Formalin fixed and
paraffin embedded Lung cancer tissue arrays and normal human lung tissue was obtained from Cybrdi
(Rockville, MD). The lung cancer tissue array contained 71 individual cases and 72 cores. Each of the
cores represents one donor. The array contained normal human lung tissues from 23 individuals, spotted
in triplicates. For both of these two tissue slides, each array spot was 1.5mm in diameter and 5 µm in
thickness. All the slides were stained with H&E staining and verified by pathologists. IHC was
performed according to manufacturer’s protocol. Tumor tissue arrays were deparaffinized in Xylene,
followed by rehydration in alcohol and then boiled in citrate buffer for antigen retrieval. Before antibody
incubation, tissue array slides were incubated with hydrogen peroxide to block any endogenous peroxide
activity and normal mouse antibody to reduce the nonspecific binding. The mouse monoclonal
p90/CIP2A antibody was added to the slides at a concentration of 1:50 and incubated at room
temperature for 1 hr, and goat anti-mouse HRP was used as secondary antibody. After washing, the
peroxides reaction was developed with 3,3'-diaminobenzidine (DAB). At last, the slides were covered
with cover slides mounted with mounting media.
Both of the slides were examined by two independent, blinded investigators. Five views
were examined per slide, and 100 cells were observed per view at 400× magnification. IHC staining of
p90/CIP2A was scored by following a semi quantitative scale (− to +++),

which evaluated the

intensity in tumor areas, and the percentage of cells showing significantly higher immunostaining than
control cells in normal lung tissues. Nuclear and/or cytoplasmic immunostaining in tumor cells was
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considered positive staining. The intensity of CIP2A staining was scored as 1 (mild), 2 (weak), and 3
(strong). Percentage scores were assigned as 0, 0%; 1, 1–50% and 2, 50–100%. The scores of each
tumor sample were multiplied to give a final score of 0–6, and the tumors were finally determined as
lower expression, score 0-3 and high expression, score 4-6.
Western-blot analysis. Cells were plated in 6-well tissue culture plates at 80% confluency and
incubated

overnight.

Cell

lysates

were

obtained

from

transduced

cells

using

cold

radioimmunoprecipitation assay buffer [20 mmol/L Tris-HCl (pH 8.0), 100 mmol/L NaCl, 10%
glycerol, 1% NP40, 0.5% sodium deoxycholate]. Twenty micrograms of protein were separated in 10%
SDS-PAGE gels and wet transferred to nitrocellulous membrane (GE Healthcare Life Sciences), then
blocked for 1 h at room temperature in TBS-T [50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 0.1%
Tween 20] buffer containing 5% nonfat milk. Membranes were then incubated overnight at 4°C or 1 h at
room temperature with the respective primary antibodies: p90/CIP2A (1:500), pJNK (1:1,000), pATF2
(1:1000), pc-Jun ( 1:1000) and actin (1:1,000). Anti-mouse or anti-rabbit secondary antibody conjugated
to horseradish peroxidase (Santa Cruz Biotechnology) was used to visualize the stained bands with an
enhanced chemiluminescence visualization kit (Santa Cruz Biotechnology).
Production of lentivirus-containing p90/CIP2A short hairpin RNA: Five p90/CIP2A short hairpin
RNAs (knock-down), ligated in pLKO.1 vector and pLOC-KIAA1524 (overexpression) were obtained
from Open Biosystems. The knock down efficiency of these shRNAs was evaluated in H1299 cells by
Western-blot, where the two showing better knock-down efficiency were chosen to produce lentivirus.
Lentivirus was produced by co-transfection of pLKO.1 control (ligated with scramble sequence) or other
pLKO.1-derived vector, or pLOC-KIAA1524 with pMD2.G, and pCMV-VSVG into HEK293T
packaging cell lines. The supernatants containing lentvirus of HEK293T were harvested at 36hrs and
72hrs post transfection. Supernatant were pooled, centrifuged to remove cells and then filtered through
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0.45µm low protein binding filter. Cells were plated in monolayer at different densities and infected
with lentivirus constructs using 8 ng/mL polybrene. The stable cell lines were selected in the presence of
1µg/ml puromycin (knock-down) or 10ug/ml blastidinin (overexpression) for two weeks.
2.3

Results

p90/CIP2A elicits auto-immune response in lung cancer patients.
To identify novel tumor-associated autoantigens in lung cancer patients, we screened the presence of
autoantibodies in 102 sera from lung cancer patients and 82 sera from normal human. Forty-nine out of
102 (48.0%) lung cancer sera contained autoantibody while 5 out of 82 normal human sera were
autoantibody positive (6.1%) (Table 2).

Interestingly, among these 49 autoantibody positive sera, 10

sera contained autoantibodies against a protein that migrates around 90 kD in SDS-PAGE gel, which is
not detected in normal human sera (Fig. 4A). Interestingly, this migration pattern is very similar as
previously identified p90/CIP2A [63]. Therefore, we directly tested whether this protein is the
previously identified p90/CIP2A by using the recombinant protein. As shown in Figure 4B, five 90 kDa
positive sera were randomly chosen for the validation. As expected, all of these five sera contain
autoantibodies against p90/CIP2A. To further validate this, recombinant p90/CIP2A was used to
immunodeplete the autoantibodies from the sera and these sera were used for Western-blot. As shown in
Fig 4B, the positive band disappeared with the p90/CIP2A immune-depleted sera. Furthermore,
frequency of p90/CIP2A autoantibodies was examined by ELISA with 105 lung cancer sera samples.
Compared to the frequency of p90/CIP2A positive sera in normal human sera (4.9%), twenty seven of
the 105 lung cancer sera (25.7%) are p90/CIP2A positive (Table 3). Taken together, p90/CIP2A elicits
auto-immune response in lung cancer patients, and therefore can be a potential serum biomarker for lung
cancer detection.
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A.

B.

Figure 4. p90/CIP2A elicits autoimmune response in lung cancer patients. (A) Representative
Western-blot results of autoantigen screening using human sera. Figure shows the some lung cancer sera
containing autoantibody against a band between 75 kD and 100 kD (serum 6 and serum 52). NHS:
normal human sera; LC: lung cancer. (B) Validation of p90/CIP2A autoantigen. Five randomly chosen
p90 positive sera were used for this validation. Antibodies against p90 containing sera were depleted
with recombinant protein and used for Western-blot.
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Table 2. Frequency of autoantibody-containing sera in lung cancer patients and normal human
sera.
____________________________________________________________________________________
Frequency
(Patients with autoantibody/
Type of diseases

No. tested

total patients with disease)
a

Lung Cancer

102

48.0% (49/102)**

Normal human sera (NHS)

82

6.1% (5/82)

a

. P value relative to NHS: * p < 0.05; ** p < 0.01
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Table 3. Frequency of autoantibody to p90/CIP2A in sera from patients with lung cancer.
____________________________________________________________________________________
Frequency
Patients with anti-p90/CIP2A/

（
Type of diseases

Lung cancer
Normal human sera (NHS)

a

No. tested

total patients with disease)a

105

25.7%（27/105)**b

82

4.9% (4/82)**b

Cutoff value: Mean + 3 SD of NHS
b

P value relative to NHS: * p < 0.05; ** p < 0.01
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p90/CIP2A is overexpressed in lung cancer
To gain insight into whether p90/CIP2A functions in lung cancer pathogenesis, we used
commercially available tumor tissue array to examine the expression level of p90/CIP2A in lung cancer
tissue specimen. A set of 72 samples of lung tumor tissues, and 63 samples of normal lung tissues were
analyzed with immunohistochemistry (IHC) by using monoclonal p90/CIP2A antibody. The p90/CIP2A
positive tissue sample is defined by having a score ranging from 1-6 (Fig. 5). Therefore, 7 out of 63
normal lung tissues showed positive immunoreactivity to p90/CIP2A, while 61 samples among the 72
lung tumor tissues are p90/CIP2A positive (Table 4). This data implied that p90/CIP2A is overexpressed
in lung cancer. The incidence of lung cancer increases with age, especially in people who are 65 years or
older. We therefore tried to define whether there is a correlation between p90/CIP2A expression and
age. However, our data did not support this link. In addition, our statistical analysis also showed that
p90/CIP2A overexpression is not correlated with gender, histology, grade or stages (Table 5). In
consistence with the previous findings, our results also showed cytoplasmic staining of p90/CIP2A (Fig.
5) [62, 63].Taken together, p90/CIP2A is overexpressed in lung cancer compared to normal lung tissue
and the resulted overexpression can be further considered as a diagnostic factor for clinical lung cancer
detection.
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Figure 5. p90/CIP2A expression in human lung cancer tissue. Representative images of IHC results of
human lung cancer tissues and normal human tissues using monoclonal mouse anti-p90/CIP2A antibody.
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Table 4. IHC results showing expression level of p90/CIP2A in lung cancer tissue specimen.

Tissue status

Total No. of Samples

No. of p90/CIP2A
positive

Normal human tissues

63

7 (11.1%)

Lung cancer tissues

72

61(84.7%)

a. p value relative to normal human lung tissue. *p<0.05, **p<0.01
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p value

<0.001 **a

Table 5. p90/CIP2A expression does not correlate with age, gender, stage and histology.

Characteristics

p90/CIP2A low expression
(score 0-3)

p90/CIP2A high
expression (score 4-6)

p value

Age
65<

28 (54.9%)

23 (45.1%)

1.00

≥ 65

11 (55%)

9 (45%)

Gender
Male

25 (47.1%)

28 (52.9%)

Female

11 (57.9%)

8 (42.1%)

I-II

19 (52.8%)

17 (47.2%)

III-IV

11 (30.6%)

25 (69.4%)

Histology
Adenocarcinoma

11 (37.9%)

18 (62.1%)

Non-adenocarcinoma

27 (60%)

18 (40%)

0.5936

Stage
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0.0935

0.0951

p90/CIP2A promotes cell proliferation of lung cancer cells.
To examine the role of p90/CIP2A in lung cancer, we evaluated the expression level of
p90/CIP2A in four non small cell lung cancer (A549, H460, H1299 and H838) and two small cell lung
cancer cell lines (H69, H146). All of these six lung cancer cell lines are expressing endogenous
p90/CIP2A (Fig. 6A). And in non-small lung cancer cell lines, H1299 is expressing relative high level of
p90/CIP2A while H460 is expressing low levels. In small cell lung cancer, H146 express relatively
higher level of p90/CIP2A than H69. To examine the role of p90/CIP2A in lung cancer cell growth, we
either deplete p90/CIP2A by shRNA or increase the expression by ectopic expression of the
recombinant p90/CIP2A. As shown in Fig. 6B, down-regulation of p90/CIP2A impaired cell
proliferation in the H1299 and H146 cell lines, while the overexpression of p90/CIP2A is associated
with increased cell proliferation. These studies suggested that p90/CIP2A promote cell proliferation of
lung cancer cells.
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A.

B.
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Figure 6. Expression of p90/CIP2A in different lung cancer cell lines and effect of p90/CIP2A in
lung cancer cell proliferation. (A) Expression of p90/CIP2A is evaluated in four NSCLC cell lines and
two SCLC cell lines using Western-blot analysis. (B) Cell proliferation were performed on four lung
cancer cell lines with either knock-down (+p90/CIP2A shRNA) or overexpression (+p90/CIP2A). For
adherent cell lines (H1299 and H460), three thousands cells for each cell line were plated triplicate in
96-well plates and MTT solution was added at day 1 and day 3. For suspension cells (H69 and H146),
cells were resuspended as single cell and 4000 cells were plated triplicate in 96-well plate, and cell
proliferation was measured the same as adherent cell. O.D absorbance was read at 570 nm. Statistical
significance was done with Students’t test.
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p90/CIP2A positively enhances c-Jun N-terminal kinase (JNK) pathways in lung cancer cells
To identify novel p90/CIP2A targeted proteins which may promote cancer cell proliferation, we
performed a global analysis of phosphorylation of key intracellular molecules from phosphoproteome
level. Total proteins extracted from H460 (H460C) cells transfected with vector control or from H460
overexpressed with p90/CIP2A (H460OV) were used as antigen to react with the phosphor-antibody
array, which was then detected with phosphor-antibody cocktails. Several molecules displayed
differentially regulated phosphrylation between the H460C and H460OV groups (with >1.3 fold
change), including: p38 alpha, pan-JNK, GSK3alpha/beta and AKT (Table 6). Of notice, the most
altered phosphorylation molecus is pan-JNK, which increased as much as 1.7 fold upon the increased
expression of p90/CIP2A.
JNK belongs to the family of mitogen-activated protein family (MAPK) which responds to stress stimuli
like UV radiation, cytokines, heat shock and osmotic shock. Activated JNK had been found to be
associated with increased cell proliferation, cell migration and cell invasion in non-small cell lung
cancer. Therefore, it is possible that p90/CIP2A may be able to regulate lung cancer progression through
this pathway. To validate our finding that p90/CIP2A regulates JNK phosphorylation in lung cancer
cells, we treated the cells with EGF to activate the growth factor-induced JNK activation. Consistent
with the finding in our phosphoproteome study, the activity of JNK is correlated with the expression
level of p90/CIP2A, as demonstrated in Fig. 7B. Furthermore, the phosphorylation of downstream
substrates of JNK, c-Jun and ATF2 were also correlated with the phosphorylation of JNK (Fig.7B).

A.
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B.
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Figure 7. p90/CIP2A promote c-Jun N-terminal kinase (JNK) phosphorylation in response to EGF
stimulation. (A) Phosphoproteomic analysis of the phosphorylation of key molecules in signaling
pathways using Human phosphorproteome array. Highlighted spots (1-4) are top molecules showing
difference between H460 cell line and H460 overexpressing p90/CIP2A cell lines. Fold of change is
measured by densitometry. (B) p90/CIP2A regulates JNK phosphorylation at different lung cancer cell
lines: H460, H838 and H1299.
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Table 6. Top four molecules which showed significant changes in response to the overexpression of
p90/CIP2A in H460 cell line.
Spot No.

Protein name

Phosphorylation site

1

p38 alpha

Thr180/Tyr182

1.35

2

JNK

Thr183/Tyr185

1.71

3

GSK3 (alpha/beta)

Ser9/Ser21

1.38

4

AKT

Ser473

1.52
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Fold of change

2.4

Discussion
Relationship between the immune system and tumorigenesis is not only an important aspect to

the understanding the relationship between immune response and progression of disease, but can also be
fundamental for the therapeutic design of the cancer treatment. Proteins involved in tumorigenesis and
cancer progression are always the target of the host’s immune system. The detection of the abnormalities
of these proteins can be a sign that the immune system is able to respond to such deregulated molecules.
Thus, the identification of novel tumor-associated autoantigens is of great importance both in clinical
development of reliable non-invasive approaches for early cancer detection, and is also a way to identify
proteins whose expression were changed during the cellular transformation and disease progression. In
this study, we found the previously identified tumor-associated autoantigens p90/CIP2A also initiates an
immune response in lung cancer patients. This result indicated that p90/CIP2A may not be a specific
antigen of gastric cancer, but it can be prognostic factor for the diagnosis of many types of cancers.
Tumor-associated autoantigens are always expressed in early stage of cellular transformation,
which were thought to be a possible clue for the sense of danger by the immune system, even though the
mechanism of the production of tumor-associated autoantibody remains unknown. The overexpressed
tumor-associated autoantigens always confer cancer cell tumorigenic ability by interrupting normal
signaling pathways. p90/CIP2A is present in embryonic development, but is silenced in most normal
adults tissues. In consistency with the previous findings, we found that p90/CIP2A is overexpressed in
lung cancers. Taken together with the results from other groups, our data further confirm the role of
p90/CIP2A in promoting tumorigenesis.
Although abundant studies had shown that p90/CIP2A is overexpressed in many types of
cancer, the role of this protein in cancer progression is still unknown. In our study, we found that
p90/CIP2A overexpression is correlated with increased phosphorylation of JNK. JNK bears both of
tumor-promoting and tumor-suppressive function dependent on the upstream stimuli. The activity of
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JNK increased along with overexpression of p90/CIP2A, which implied that p90/CIP2A may prime the
JNK to tumor-promoting function in response to mitogen stimulation. Interestingly, the two identified
PP2A inhibitors, I2PP2A and small t antigen have similar roles to p90/CIP2A in promoting JNK
phosphorylation and AP-1 transcriptional activity. However, the exact mechanism of how these PP2A
inhibitors, including p90/CIP2A, are able to modulate the JNK phosphorylation is still unknown, since
PP2A is able to target several molecules in this pathway. Further investigation should be focused to
resolve this issue.
Taken together, our study found that p90/CIP2A is a cytoplasmic tumor-associated autoantigen
in lung cancer, whose overexpression can be sensed by host immune system. The aberrantly
overexpressed p90/CIP2A is associated with the increased cell proliferation of lung cancer cells. The
underlying mechanism of p90/CIP2A for cancer progression is through the c-myc-dependent pathway
and c-myc-independent pathway JNK-c-Jun/ATF2, identified in this study.
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Chapter 3: p90/CIP2A regulates CREB phosphorylation by modulating AKT-associated PP2A
phosphatase activity
3.1

Introduction

Lung cancer is one of the most common cancer types, and one that causes most of the cancer-related
deaths throughout the world in recent years [1]. According to the latest data from American Cancer
Society, there will be about 221,130 new cases of lung cancer (both small cell and non-small cell) in the
United States in 2011 and about 156, 940 people would die from it at the same year [1]. Although the
factors that cause lung cancer have not been well defined, like many other types of cancer, some
common genetic lesions have been identified as important triggers for lung cancer formation. Genes like
epidermal growth factor receptor (EGFR), V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), c-myc, APC, LKB1, p53 and protein phosphatase 2A (PP2A) are the most commonly activated
oncogenes or inactivated tumor suppressors in lung cancer [13, 18, 36, 105].
PP2A, a large protein family with intrinsic serine/threonine phosphatase activity, is a known tumor
suppressor by targeting cancer-related molecules or pathways like AKT, MAPK and beta-catenin [48].
The holoenzyme consists of a regulatory subunit (B subunit), which confers substrate selectivity, a
catalytic subunit (C subunit), and a scaffold subunit, which brings B and C subunits together [48].
Inhibition of PP2A phosphatase activity has been found to be a prerequisite for cellular transformation
in epithelial cells [37]. The mechanisms involved in the inactivation of PP2A phosphatase activity
include genetic mutations, epigenetic silencing or inhibition [36]. Missense or deletion mutations of the
A and B subunits were frequently observed in lung cancer, breast cancer and colon cancer, but mutations
of the C subunit are rare [36]. The restoration of PP2A phosphatase activity by re-introduction of the
wild type PP2A subunit to cancer cell lines can lead to decreased cell proliferation, cell scencese or
apoptosis [36].
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Besides mutations, PP2A can also be inactivated by exogenous or endogenous factors. Chemicals like
okadaic acid, viral proteins like small t antigen and cellular proteins like I1PP2A and I2PP2A were all
identified as PP2A inhibitor , which promote cellular transformation and cancer progression [36].
However, few endogenous PP2A inhibitors had been identified so far. p90/CIP2A was a recently
identified endogenous PP2A inhibitor in human malignancies . This protein was actually identified as a
tumor-associated autoantigen in gastric patients ten years ago. Although this protein was found to be
tightly regulated during development, the function of this protein was largely unknown due to the lack
of homologies to any other function-known proteins at the time of identification. In search of PP2A
interacting proteins in Hela cells, Juttia et al. used PP2A A subunit as the bait in tandem-affinity
purification, and established that the protein pulled-down by PP2A was the p90 autoantigen. The knockdown of this protein can greatly impair cell proliferation and in vivo tumor growth. One of the
mechanism is involved in the ability of p90/CIP2A to inhibit c-myc-associated PP2A phosphatase
activity by an unknown manner, thus named as cancerous inhibitor of PP2A (CIP2). Following studies
by examining tissue specimen of different cancer types revealed that p90/CIP2A was overexpressed in
cancer tissues but not in normal tissue. Although p90/CIP2A is able to inhibit PP2A phosphatase
activity, previous data strongly suggest that it has substrate selectivity, since the phosphorylation of
other PP2A substrates like p53 and MDM2 were unaffected. So far, only a few p90/CIP2A targets have
been identified. In addition to c-myc, UNC5B and AKT were also found to be targets of p90/CIP2A.
Interestingly, both of these proteins raised the involvement of p90/CIP2A in anti-apoptotic function.
The molecular mechanism of p90/CIP2A in cancer has been detected by transcriptomic studies as a
whole. However, it still lacks studies at the proteome level, which do not necessarily correlate with
mRNAs. Two-dimensional electrophoresis-based proteomic approach is a widely-adopted method to
study the function of a gene by interpreting the global protein profile change. The integration of
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differentially expressed proteins in database, including all the known pathways, and transcription factors
have proved to be an effective way to uncover novel function of certain proteins.

3.2

Materials and methods

Production of lentivirus-containing p90/CIP2A short hairpin RNA: Five p90/CIP2A short hairpin
RNAs, ligated in pLKO.1 vector, were obtained from Open Biosystems (Huntsville, AL). The knock
down efficiency of these shRNAs was evaluated in H1299 cells by Western-blot, where the two showing
the better knock-down efficiency were chosen to produce lentivirus. Lentivirus was produced by cotransfection of pLKO.1 control (ligated with scramble sequence) or other pLKO.1-derived vector with
pMD2.G and pCMV-VSVG into HEK293T packaging cell lines. The supernatants containing lentivirus
of HEK293T were harvested at 36hrs and 72hrs post transfection. Supernatant were pooled, centrifuged
to remove cells and then filtered through a 0.45µm low protein binding filter. Cells were plated in
monolayer at different densities and infected with lentivirus constructs using 8 ng/mL polybrene. The
stable cell lines were selected in the presence of 1µg/ml puromycin for two weeks.
Cell proliferation, clonogenic assay, and anchorage-independent cell growth assay. The shRNA for
p90/CIP2A lentivirus-transduced cells and control-transduced cells were plated quadruplicate in 96
wells plates at a density of 3 × 103/100µl medium for each well. After a 3-day culture, 15µl of the dye
solution was added to each well and incubated at 37oC for another 4 hrs. At the end of the incubation,
100µl stop solution was added to each well and colometric absorbance was read in the SpectraMax Plus
(Molecular Devices) at 570nm. Cell free medium was used as mock control.
To measure the effects of knockdown on tumor cell colonogenic expansion, p90/CIP2A shRNA–
transduced cells and control shRNA transduced cells were trypsinized and resuspended in complete
growth medium to form single cells. For each group of cells, 5 × 103 cells were plated in 100-mm petri
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dish (BD bioscience) and incubated for 15 days. Medium was changed every three days. At the end of
incubation, colonies were fixed with 10% formalin and stained with crystal violet. Number of colonies
were counted using Image J software (NIH.)
Colony formation ability on soft agar was evaluated. Briefly, 2.5 mL base layer consisting of 0.4%
Nobel agar medium were prepared in 100mm petri dish (BD biosciences, Bedford, MA). p90/CIP2A
shRNA–transduced and control lentivirus–transduced cells were trypsinized, centrifuged, resuspended in
0.4% agarose medium (equal volumes of 0.8% agarose and 2X RPMI1640 containing 20% FBS culture
medium), and plated onto the top agar at 12,500 cells per well. The cells were kept wet by adding a
small amount of 2.5ml complete RPMI 1640 growth medium (Life Technologies), which contained 10%
FBS (Carlsbad, CA), and incubated for 3 wk at 37°C. Colonies were stained with crystal violet and
counted under the microscope.
PP2A phosphatase activity assay. Measurement of PP2A phosphatase activity was performed by using
the RediPlate™ 96 EnzChek® Serine/Threonine Phosphatase Assay Kit (Invitrogen, CA) . Cell lysates
were prepared by using low detergent buffer (1% Nonidet P-40, 10 mM HEPES, 150 mM NaCl, 10%
glycerol, 1 mM PMSF and complete protease inhibitor cocktail). Total of 50 µl cell lysates were
incubate with 1XPP2A phosphatase reaction buffer for 30mins at 37oC. Fluorescence was measure using
excitation at 355nm and emission at 485nm. The fluorescence intensity was normalized to the
expression level of PP2A catalytic domain.
Western-blot analysis. Cells were plated in 6-well tissue culture plates at 80% confluence and
incubated

overnight.

Cell

lysates

were

obtained

from

transduced

cells

using

cold

radioimmunoprecipitation assay buffer [20 mmol/L Tris-HCl (pH 8.0), 100 mmol/L NaCl, 10%
glycerol, 1% NP40, 0.5% sodium deoxycholate]. Twenty micrograms of protein mixture were separated
on 10% SDS-PAGE gels, were wet-transferred to nitrocellulose membrane (GE Healthcare Life
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Sciences) and then blocked for 1 h at room temperature in TBS-T [50 mmol/L Tris-HCl (pH 7.5), 150
mmol/L NaCl, 0.1% Tween 20] buffer containing 5% nonfat milk. Membranes were then incubated
overnight at 4°C or 1 h at room temperature with the respective primary antibodies: anti-p90/CIP2A
(1:500), anti-c-myc (1:1,000), anti-PP2A catalytic domain (1:500) and anti-actin (1:1,000). Anti-mouse
or anti-rabbit secondary antibody conjugated to horseradish peroxidase (Santa Cruz Biotechnology,
Santa Cruz, CA) was used to visualize the stained bands with an enhanced chemiluminescence
visualization kit (Santa Cruz Biotechnology, Santa Cruz, CA).
Sample preparation and 2-Dimensional electrophoresis: Cells transduced with either control
lentivirus or p90shRNA1 were directly lysed in 2-DE rehydration sample buffer (7 M urea, 2 M thiourea,
4% CHAPS, 80 mM DTT, and 1% carrier ampholyte pH 3−10). Protein concentration was measured
with Brandford assay (Bio-rad). One hundred and twenty five micrograms of protein were loaded to
11cm pH 3-10 Isoelectric focusing (IEF) gel strip,

where IEF was carried out for 8000 Vh. IEF gels

are equilibrated in equilibration buffer containing 2% DTT for 15 mins, followed by equilibration in
equilibration buffer containing 2.5% iodiactomine for another 15 mins. The gels were transferred to the
second-dimension electrophoresis using 10% acrylamide gel. Protein spots were visualized by staining
with Coomassie blue (CBB) R250.
Protein digestion. The CBB-stained protein spots were cut from the gel and destained three

times

with 100 μL of 50 mM ammonium bicarbonate/50% acetonitrile (ACN) for 30 min at ambient
temperature. The destained gel pieces were then completely dried in a SpeedVac vacuum concentrator
(Savant Instruments, Farmingdale, NY). Gel pieces were reswollen with 8 μL of 25 mM ammonium
bicarbonate containing 10 ng of trypsin at 4 °C for 1 h. After 13.5 h of incubation at 37 °C, the gel
pieces were vacuum-dried, 8 μL of 50 mM ammonium bicarbonate was added, and the samples were
incubated at 37 °C for 1 h. The supernatant was transferred into another microtube, and 8 μL of 2.5%
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trifluoroacetyl (TFA)/50% ACN was used for the second step of extraction at 30 °C for 1 h. Then both
supernatants were combined with the first one. Finally, in order to extract hydrophobic peptides, 8 μL of
100% ACN was used at room temperature for 1 h, and the supernatant was also combined with the
previous supernatants. The combined supernatants were then dried in a SpeedVac and redissolved with 2
μL of 0.5% TFA.
MALDI-TOF/MS Analysis. As previously described, 0.5 μL of the sample solution, along with
equivalent matrix solution (α-cyano-4-hydroxycinnamic acid), was mixed and applied onto the MALDITOF target for MALDI-TOF/MS analysis. MALDI-TOF spectra were calibrated using trypsin
autodigestion peptide signals and matrix ion signals. MALDI analysis was performed using a fuzzy
logic feedback control system (Reflex III MALDI-TOF system Bruker, Karlsruhe, Germany) equipped
with delayed ion extraction. Peptide masses were searched against the Swiss-Prot database using the
MS-Fit program (http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm) or the NCBI database using the
MASCOT program (http://www.matrixscience. com) against Homo sapiens database in NCBI.
Bioinformatics analysis: The gene interaction network was built with Pathway Studio software. All the
differentially expressed proteins are entered into the database and set filter as “Promoter Binding" to
create the shortest pathways, which give predictions on transcription factor candidates.
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3.3

Results

Establishment of stable cell line expressing p90/CIP2A shRNA.
First, we examined the expression of p90/CIP2A in four different lung cancer cell lines: A549,
NCI-H838, NCI-H1299 and NCI-H460. As shown in Figure 8, all of the examined lung cancer cell lines
expressed endogenous p90/CIP2A. While NCI-H1299 contained the most abundant protein, NCI-H460
expressed the least amount of p90/CIP2A in these four cells lines, as compared to the expression level of
actin. Therefore, the H1299 cell line was used as our research model to generate stably expressing
p90/CIP2A shRNA cell lines by lentiviral-mediated transduction which achieved >90% knocking-down
effect as determined by western-blot. According to previous data showing that the loss of p90/CIP2A
will induce the degradation of c-myc by restoring c-myc associated PP2A phosphatase activity in Hela
cells, we also measured the expression level of c-myc and PP2A phosphatase activity. In consistence
with previous results, the knock-down of p90/CIP2A in H1299 also lead to decreased levels of c-myc
(Fig. 8B) and increased PP2A phosphatase activity in the total cell lysates (Fig. 8 C). Therefore, this
stable cell line reinforced what the previous results showed.
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A.

B.
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C.

Figure 8. p90/CIP2A expression in lung cancer cell lines and p90/CIP2A knock-down in H1299. A)
p90/CIP2A expression was examined in four different lung cancer cell lines: A549, NCI-H838, NCIH1299 and NCI-H460. B) Western-blot results of p90/CIP2A, c-myc and actin after knock-down of
p90/CIP2A in H1299 lung cancer cells (C) PP2A phosphatase activity assay. Total cell lysates extracted
from either control group or shRNA p90 treated groups are loaded to measure the PP2A phosphatase
activity by using DiMUF as the substrates (upper panel). Fluorescence readings were normalized to the
expression level of PP2A catalytic subunit (lower panel).
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Depletion of p90/CIP2A impairs cell proliferation, clonogenic ability and anchorage-independent
growth of H1299 cell line.
As previously reported, p90/CIP2A plays crucial roles in cell proliferation by regulating the
expression of oncoprotein c-myc. We intended to determine whether this protein could have a similar
function in lung cancer cells. By knocking-down p90/CIP2A in

H1299 lung cancer cell line via

shRNA, we found that the proliferation rate of p90/CIP2A shRNA transduced cell line was greatly
impaired. Proliferation decreased to only 59% (Fig 9A, upper panel) when compared to the cells
infected with shRNA control. These data suggested that p90/CIP2A increase cell proliferation of lung
cancer cells.
Clonogenic expansion is an ability of tumor cells to grow from a single cell. Previous results
showed that knock-down of p90/CIP2A in Hela cells can impair its ability to form foci in culture dish.
Therefore, we tested whether it had the same effects in lung cancer cell lines. By plating on the petridish for two weeks, the down-regulation of p90/CIP2A in H1299 decreased the foci locus to 62% as
compared to vector control cell line (Fig 9 B). In addition, the number of foci of the knock-down cell
line is smaller than the control group (Data not shown).
Similarly, anchorage-independent growth showed that the p90/CIP2A down-regulation has only
50% of colonies formed in soft agar of the cells transduced with control shRNA (Fig 9C). This data
suggest that p90/CIP2A is essential for tumor cell growth in vitro.
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A.

B.

*p<0.05
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C.

*p<0.05

Figure 9. Depletion of p90/CIP2A induce decreased cell proliferation, clonognic expansion, soft
agar growth and PP2A phosphatase activity. A) Cell proliferation assay of the effect of knock-down
p90/CIP2A in H1299 using MTTs assay. B) Clonogenic expansion assay in H1299 cancer cells. 5X10 3
control cells or cells transduced with shRNA are seeded in 100-mm petri dish for 15 days. Foci are fixed
in 10% formalin, stained with crystal violet, scanned with Quantity One software and analyzed with
Image J. C) Anchorage-independent cell growth. 1.25X104 cells are resuspended in 0.4% agarose,
poured to base agar containing 0.8% Nobel agar and incubated to three weeks. Colonies are stained with
crystal violet and counted under microscope. D) PP2A phosphatase activity assay. Total cell lysates
extracted from either control group or shRNA p90 treated groups are loaded to measure the PP2A
phosphatase activity by using DiMUF as the substrates. All statistic significance is calculated by using
Students' t test.
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Proteomic analysis of the output upon the loss of p90/CIP2A in H1299 lung cancer cell line.
The current understanding of the function of p90/CIP2A is still limited to its ability to regulate
the expression of c-myc. To gain insight into how p90/CIP2A regulates tumor growth, we utilized 2-D
electrophoresis and mass spectrometry-based proteomic approach to systematically investigate the
differential expression profile of H1299 cancer cell line on the context of wild type cell line or cell line
stably expressing p90/CIP2A shRNA. By comparing the 2-D profile to these two groups, we
quantitatively detected 49 differentially expressed protein spots, which showed at least 1.5 fold change
(Fig. 10).
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Figure 10. Representative 2-DE gel. Equal amount of proteins were loaded to IEF strip (11cm, pH3-10) and
isoelectric focusing for 8000 vhrs. Gels are equilibrated before loading for the second-dimension. The SDSPAGEs are stained with Coomassie R-250, scanned and analysed with PDQUEST software. Protein spots with
more than 1.5 fold changes are considered as differentially expressed proteins, which are indicated as arrows in
the gel.
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Protein classification and annotation
According to the reported function of these proteins, we found that a majority of these altered
proteins belong to functional classes of metabolism, signal transduction and transcriptional and
translational control (Fig 11). Proteins like phosphoglycerate mutase 1 (PGM), α-enolase and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are involved in different steps of glycolysis by
catalyzing chemical reactions (Table 7) [106-108]. Tumor cells always exhibited increased glycolysis to
generate ATP to support their growth under aerobic conditions, which is known as Warburg effect [77].
The loss of p90/CIP2A impairs the expression of these proteins and indicates that p90/CIP2A may
indirectly affect their expression through c-myc, since c-myc is known to promote the aerobic glycolysis
of cancer cells. Other metabolism-related proteins like nucleoside diphosphate kinase (NDK) play roles
in catalyzing the exchange of phosphate groups between different nucleoside diphosphates [109].
Nucleophosmin, which is encoded by nm23-H1 gene, has been reported to be overexpressed in many
different type of malignancies [110]. The clinical study showed that its overexpression is strongly
associated with tumor cell motility, invasion and metastasis [110].
Twenty four percent of the differentially expressed proteins are associated with transcriptional
and translational control. Among these proteins, SAP-domain containing ribonucleoprotein (CIP29) and
heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1) are known to be able to bind nucleotide and
regulate RNA stability and localization (Table 1) [111, 112]. CIP29, like p90/CIP2A, is a fetal protein
that is only expressed during embryonic stage and becomes silenced in adult tissue [111]. This protein is
overexpressed in breast and pancreatic tumors. hnRNP H1 is a mRNA binding protein and its interaction
with target mRNA can determine their subcellular localization [112]. The function of this protein in
cancer is not well understood, but it has been reported to be involved in anti-cancer drug resistance [112].
Protein DJ-1 and far upstream element-binding protein 2 (FUBP-2) can facilitate gene transcription [113,
114]. For example, protein DJ-1 can positively regulate the transcription of androgen receptor (AR) in
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the nucleus [113]. FUBP-2 and its family protein FUBP-1 are known to be involved in the
transcriptional control of c-myc. The knock-down of this protein will lead to decreased cell proliferation
and xenographt tumor growth [114]. Other proteins like elongation factor 2 (eEF2), acidic leucine-rich
nuclear phosphoprotein 32 (ANAP32), ruvB-like 1 et al are participating in diverse cellular function
such as translation elongation, nuclearsome assembly and transcription [115-117].
Another major functional class is related to signal transduction and protein degradation (Table
6). This functional class protein consists of several cancer-related genes (Table 6). Annexin A5 and 143-3 ε are proteins of great importance in regulating cancer cell proliferation [118, 119]. Proteins like
Annexin A1 and EBP1 have anti-proliferative effects in cancer. 14-3-3 ε exerts its effect through
binding to other signal transduction molecules by recognizing the phosphoserine-containing residue. It
can promote cell proliferation by interacting with the key components in the RAS and MAPK pathways
[119]. EBP1 is an ErbB-3 binding protein, which inhibit cell proliferation and induce cell differentiation
in breast cancer cells. Yet, it is unknown how this protein inhibits cell proliferation, since it act as
transcription factor or transcription co-regulator, which is normally sequestered in the cytoplasm as
inactive form until it has been stimulated with proper ligands [120].
Some proteins related to the cytoskeleton have also been identified: septin, F-actin-capping
protein subunit-beta, stathamin-1 and microtubule-associated protein RP/EB family member (MAPRE1).
These proteins participate in chromosome stability, cell polarity and cytokenesis [121, 122]. Except for
F-actin-capping protein subunit-beta, all of the other three proteins have been confirmed to be related to
cancer (Table 8, 9).
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Figure 11. Protein classification by function. The differentially expressed proteins are classified by
their reported function. The gene function was obtained from Gene Ontology (GO) database.
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Table 7. Summary of differentially expressed proteins.
Spot
Protein Name
No.
Metabolism
5
Glucosidase II

Accession
No.

Score

MW/pI Function

gi|2274968

242

9

UDP-Nacteylglucosamine
pyrophosphorylase 1

gi|3273316

313

107,28 breaking down complex carbohydrates
9
Da/5.74
57,421 catalyzes the final step of UDP-N
Da/5.92 acetylglucosamine (UDP GlcNAc) biosynthesis
from fructose 6 phosphate.

15, 16

alpha-enolase

gi|693933

420

20

glyceraldehyde-3phosphate
dehydrogenase
L-lactate
dehydrogenase

gi|7669492

269

gi|4557032

313

36,900 It converts pyruvate, the final product of glycolysis
Da/5.71 to lactate when oxygen is absent or in short supply

dimethylarginine
dimethylaminohydrolas
e2
glutathione Stransferase

gi|7524354

267

29,911 degrading methylarginines
Da/5.53

gi|2204207

318

23,595 catalyse the conjugation of reduced glutathione to
Da/8.91 electrophilic centers on a wide variety of substrates

Phosphoglycerate
gi|4505753
mutase 1
37
nucleoside diphosphate gi|35068
kinase A
43
inositol
gi|443382
monophosphatase 1
Transcriptional and translational regulation
6
elongation factor 2
gi|4503483

344

28,900 Catalyzes glycolysis
Da/6.67
20,740
Da/5.83
30,437
Da/5.16

24

26

32

34

7

305
283

395

far upstream elementbinding protein 2
ruvB-like 1

gi|11958950 449
2
gi|4506753 569

13,17

heterogeneous nuclear
ribonucleoprotein H1

gi|5031753

576

21

nascent polypeptideassociated complex
subunit alpha

gi|5031931

253

12

47,421 catalyzes glycolysis
Da/7.01
36,201 catalyzes glycolysis
Da/8.57

96,246
Da/6.41
77,060
Da/6.84
50,538
Da/6.02

Translation elongation

23,370
Da/9.6

prevents short recently synthesized ribosomeassociated polypeptides from inappropriate
interactions with cytosolic proteins

Facilitate c-myc transcription

involve in transcriptional activation of select genes
principally by acetylation of nucleosomal histone
H4 and H2A.
49,484 influence pre-mRNA processing and other aspects
Da/5.89 of mRNA metabolism and transport

59

22

29

acidic leucine-rich
nuclear phosphoprotein
32
prohibitin

gi|5453880

141

28,682 E4F1-mediated transcriptional repression.
Da/3.99

gi|4505773

588

29,843 modulate transcriptional activity by interacting
Da/5.57 with various transcription factors, including nuclear
receptors
23,713 participate in important transcriptional or
Da/6.1 translational control of cell growth, metabolism and
carcinogenesis
20,050 positive regulator of androgen receptor-dependent
Da/6.33 transcription
25,329 Translation iniation
Da/4.72

33

SAP domain-containing gi|32129199 271
ribonucleoprotein

35

protein DJ-1

gi|31543380 279

40

eukaryotic translation
initiation factor 3

gi|10801345 156

48

chromobox protein
homolog 1

gi|5803076

237

21,519 Recognizes and binds histone H3 tails methylated
Da/4.85 at 'Lys-9', leading to epigenetic repression

Signal transduction and protein degradation
14
erbB3 binding protein
gi|4099506
EBP1

292

38,320 Inhibit androgen receptor-mediated transcription
Da/6.13

39

gi|15214610 177

19,759 regulation of apoptosis, and microtubules
Da/4.84 stabilization

gi|4185720

447

27

translationallycontrolled tumor
protein
ubiquitin carboxyterminal hydrolase L1
14-3-3 protein epsilon

gi|5803225

297

41

annexin A5

gi|4502107

581

28

proteasome subunit
alpha type-1 isoform 2

gi|4506179

246

23,354
Da/5.33
29,326
Da/4.63
35,971
Da/4.94
29,822
Da/4.24

49

ubiquitin-conjugating
gi|4885417 235
enzyme E2 K
proteasome subunit beta gi|22538467 442
type-4

30

31

42

proteasome subunit
alpha type-3
Protein trafficking
1
nuclear autoantigenic
sperm protein isoform 2
19
annexin A1

gi|4506183

202

gi|27262628 493

23

Clathrin chain A

gi|11958295 607
0
gi|4502899 243

44

Ran-specific GTPase-

gi|542991

144

Protein degradation
mediate signal transduction by binding to
phosphoserine-containing proteins
anticoagulant protein that acts as an indirect
inhibitor of the thromboplastin-specific complex
Protein degrdation

22,507 ubiquitin conjugating enzyme, protein degradation
Da/5.33
29,242 Protein degradation
Da/4.21
28,643 Protein degradation
Da/4.26
85,471
Da/4.26
40,475
Da/6.57
23,704
Da/4.43
23,610
60

transporting histones into the nucleus of dividing cel
promotes membrane fusion and is involved in
exocytosis
endocytosis
GTPase activator for the nuclear Ras-related

activating protein
47

endoplasmin precursor

gi|4507677

379

Da/5.19 regulatory protein Ran, converting it to the putatively
inactive GDP-bound state
92,696 processing and transport of secreted proteins
Da/4.76

Cytoskeletal proteins
2
Drebrin

gi|18426913 336

18

septin-2

gi|4758158

342

25

F-actin-capping protein
subunit beta
Stathmin 1/oncoprotein
18

gi|4826659

407

gi|5031851

255

microtubule-associated
protein RP/EB family
member
Protein synthesis
10
transfer RNA-Trp
synthetase
Channel protein

gi|6912494

314

30,151 regulate microtubule dynamics and their
Da/5.02 interactions with intracellular structures

gi|340368

263

53,396 have aminoacylation activity
Da/5.32

45

nuclear chloride
channel
Chaperon
3
Hsp90AA1

gi|4588526

480

27,249 stabilization of cell membrane potential
Da/5.09

4

heat shock cognate 71
kDa

gi|62897129 527

11

T-complex protein 1
subunit beta
prostaglandin E
synthase 3
calreticulin precursor

gi|5453603

38

46

36
8

gi|83699649 449

589

gi|23308579 80
gi|4757900

243

72,078
Da/5.02
41,689
Da/6.15
30,952
Da/5.36
17,292
Da/5.76

actin-binding protein thought to play a role in the
process of neuronal growth
causes actin stress fibers to disintegrate and cells to
lose polarity.
regulates growth of the actin filament
regulation of the microtubule filament system by
destabilizing microtubules. It prevents assembly
and promotes disassembly of microtubules.

98,652
Da/4.94
71, 083
Da/5.37

Help protein folding in general and prevent protein
aggregation
binds to nascent polypeptides to facilitate correct
protein folding

57,794
Da/6.01
18,971
Da/4.35
48,283
Da/4.29

molecular chaperone help the folding of actin and
tubulin
for proper functioning of the
Glucocorticoid and other steroid receptors.
Molecular calcium-binding chaperone promoting
folding, oligomeric assembly and quality control in
the ER
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Table 8. Up-regulated proteins after the loss of p90/CIP2A
Spot No.

Protein Name

Fold of change Cancer-related?

5

Glucosidase II

1.56

No

6
11
9

elongation factor 2
T-complex protein 1 subunit beta
UDP-N-acteylglucosamine
pyrophosphorylase 1
transfer RNA-Trp synthetase
heterogeneous nuclear ribonucleoprotein
H1
ruvB-like 1e
erbB3 binding protein EBP1
annexin A1
septin-2
nuclear chloride channel
endoplasmin precursor
inositol monophosphatase 1
SAP domain-containing
ribonucleoprotein
annexin A5
microtubule-associated protein RP/EB
family member
ubiquitin-conjugating enzyme E2 K
chromobox protein homolog 1

1.53
1.72
1.73

Yes
Yes
No

1.65
1.57

No
No

1.82
2.13
2.34
2.1
1.78
2.03
1.96
1.54

No
Yes
Yes
Yes
No
Yes
Yes
Yes

2.03
1.79

Yes
Yes

1.63
1.97

Yes
Yes

10
13, 17
12
14
19
18
45
47
43
33
41
46
49
48
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Table 9. Down-regulated proteins after the loss of p90/CIP2A.
Spot
No.
1

Protein Name

Fold of change Cancer-related?

nuclear autoantigenic sperm
protein isoform 2

2.31

No

2

Drebrin

2.27

No

3

Hsp90AA1

1.77

Yes

4

heat shock cognate 71 kDa

1.68

Yes

8

calreticulin precursor

1.54

No

7

far upstream element-binding
protein 2

2.13

Yes

36

prostaglandin E synthase 3

1.79

Yes

39

translationally-controlled tumor
protein
ubiquitin carboxy-terminal
hydrolase L1
prohibitin
F-actin-capping protein subunit
beta
nascent polypeptide-associated
complex subunit alpha
14-3-3 protein epsilon
glutathione S-transferase
dimethylarginine
dimethylaminohydrolase 2
clathrin light chain A
acidic leucine-rich nuclear
phosphoprotein 32 family
member A

1.43

Yes

1.25

Yes

1.98
2.1

Yes
No

1.98

Yes

2.15
1.73
1.73

Yes
Yes
No

1.84
2.15

Yes
Yes

Stathmin 1/oncoprotein 18
proteasome subunit alpha type-3
alpha-enolase
glyceraldehyde-3-phosphate
dehydrogenase
L-lactate dehydrogenase
proteasome subunit beta type-4
protein DJ-1
Phosphoglycerate mutase 1

2.31
1.56
1.99
2.12

Yes
No
No
Yes

2.32
1.57
1.64
1.74

Yes
No
Yes
No

30
29
25
21
27
32
26
23
22

38
28
15, 16
20
24
31
35
34

64

40
42
44

37

eukaryotic translation initiation
factor 3
proteasome subunit alpha type-3
Ran-specific GTPase-activating
protein

1.57

No

1.91
1.23

No
Yes

nucleoside diphosphate kinase A

2.15

Yes

65

Validation of differentially expressed proteins.
To confirm the differentially expressed protein identified in the 2-D gels, three cancer-related
proteins, Annexin A1, 14-3-3 epsilon and EBP1, were chosen to confirm the altered expressions with
Western-blot. As shown in figure 7, the protein changes are in consistent with our 2-DE results (Fig. 12).
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Figure 12. Validation of the differentially expressed proteins by Western-blot. H1299 cancer cell
lines are transiently transfected with shRNAcontrol or shRNA1 or shRNA2. Protein expression level of
EBP1, Annexin A1 and 14-3-3 epsilon were evaluated with Western-blot with specific antibodies (Left
panel). The corresponding protein spots were enlarged (middle panel) and the expression changed was
quantified with PDQUEST (Right panel).
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Gene interaction network predict p90/CIP2A may involve in the regulation of c-myc, CREB, ETS1 and ESR-1 transcriptional factors.
To examine whether there is an interaction between the differentially expressed proteins, these
proteins were entered into the software Pathway Studio. By searching the promoter binding filter, we
found that several of the differentially expressed proteins were either independently regulated by four
transcription factors, including c-myc, CREB, ETS-1 and ESR-1 or co-regulated among them (Fig. 13).
ESR-1 (Estrogen receptor 1) is a ligand-activated transcription factor. It normally resides in
the plasma membrane in an inactive form. Upon hormone binding, ESR-1 can translocate to the nucleus
and form homodimers or heterodimers with estrogen receptor 2 (ESR-2) to drive downstream gene
transcription. Overexpression of estrogen receptors have been observed in many different types of
cancer, especially in hormone-dependent cancers like breast cancer and prostate cancer [123]. ETS-1
(protein c-ETS-1), encoded by ETS-1 gene, belongs to ETS gene family, which shares the ETS domain.
ETS-1 is expressed both in normal cell and cancer cells. This proto-oncogene regulates the expression of
several angiogenic and extracellular matrix remodeling factor, which promote an invasive phenotype
[124]. c-myc is a transcription factor playing roles in development and cell transformation. It is involved
in a wide range of biological processes including metabolism, DNA replication, transcription, cell
growth, differentiation and apoptosis by controlling ~ 15% genes from flies to mammalian cells [57,
125]. c-myc is an essential proto-oncogene for cell transformation, since the c-myc knock-out

mouse

embryonic fibroblasts cannot be transformed by other oncogenes. The mutation of gene by gene
amplification is very common in different types of cancers, which promotes cell proliferation and
metabolic rates [57, 126]. CREB (cyclic AMP responsive element binding protein), is a transcription
factor involved in diverse range of biological processes like cell proliferation, cell survival and glucose
metabolism [126]. The most significant role of this protein is in neural plasticity and long-term
formation [126]. The relationship between CREB and cancer is inferred from the fact that CREB can
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be activated by growth factors, which normally promote cell proliferation in cancer cells [126]. Of
notice, two of the transcription factors, c-myc and ETS-1, have been reported to be associated with
p90/CIP2A. p90/CIP2A can regulate the c-myc stability by inhibiting its associated PP2A phosphatase
activity while ETS-1 promote the overexpression of p90/CIP2A through MEK-ERK pathway [127].
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Figure 13. Construction of gene interaction network by using Pathway Studio. The differentially
expressed proteins are searched against potential transcription factors in Pathway studio database. The
four highlighted proteins, MYC, ESR1, CREB and ETS are the nexus proteins, which share common
protein targets.
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p90/CIP2A may regulate CREB transcription through growth factor mediated AKT-CREB
pathway.
To confirm our bioinformatics prediction, we directly tested whether p90/CIP2A can regulate
the activity of CREB. The activation of CREB is dependent on the phosphorylation at its serine 133
residue [128]. There are multiple pathways which can regulate the phosphorylation event. Second
messengers like calcium and cAMP activate extracellular-regulated kinases (ERK) or protein kinase A
(PKA) to induce CREB phosphorylation. Growth factors like EGF can also trigger CREB
phosphorylation by activating the PI3K-AKT and p38 signaling pathways [128] . Therefore, we tested
whether the loss of p90/CIP2A would lead to impaired CREB phosphorylation at S133 by using
phosphor specific antibody. After being starved for 24 hrs, H1299 and H1299-p90/CIP2A shRNA cells
were treated with either KCl, which depolarized cell membrane and induced calcium influx, forskolin or
serum. Interestingly, the treatment with KCl and forskolin did not significantly alter the phosphorylation
of CREB. In contrast, the serum treated H1299-p90shRNA showed large reduction of phosphorylated
CREB (Fig. 14A). This result implied that p90/CIP2A may affect the CREB phosphorylation through
growth factor stimulated pathway.
One of the most important growth factors associated with lung cancer is the EGF. Upon ligand
binding, the downstream MAPKs will be activated, which lead to cell proliferation. Therefore, we
examined the phosphorylation of the proteins, which are known to regulate the phosphorylation of
CREB. Interestingly, only the phosphorylation of AKT is downregulated, while the phosphorylation of
p90RSK and p38 is not affected (Fig. 14B). Furthermore, the overexpression of p90/CIP2A also
promote the phosphorylation of CREB at S133 through AKT, whose phosphorylation was also elevated
(Fig. 14C&D). Taken together with the previous results that p90/CIP2A can decrease AKT associated
PP2A phosphatase activity, we conclude that one of the downstream targets of AKT is CREB (Fig. 14E).
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A.

B.

C.
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D.

E.

Figure 14. p90/CIP2A regulate CREB phosphorylatio through AKT. A) H1299 transduced with
either control shRNA or shRNA1 were serum starved for 16hrs and then treated with either KCl
(60mM), forskolin (10μM) or complete growth medium containing 10% FBS. B) Western-blot results
shows that treatment with EGF resulted in reduced phosphorylation of AKT but not p90RSK and p38,
all of which are upstream kinases of CREB. C) & D) p90/CIP2A is overexpressed in H1299 or knockdown in H838 and A549 cell lines and the phosphorylation of CREB and AKT was evaluated. E)
Evaluate of AKT-associated PP2A phosphatase activity.
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3.4

Discussion
Although the protein p90/CIP2A was identified more than ten years ago, the function of this

protein was recently discovered. Serving as an endogenous PP2A phosphatase activity inhibitor, this
protein was found to specifically recognize the PP2A-c-myc complex, and extended the half-life of cmyc, leading to cellular transformation and increased cell proliferation. Previous studies demonstrated
that this protein was overexpressed in a wide variety of cancer types including prostate cancer, breast
cancer, non-small cell lung cancer, cervical cancer and gastric cancer [67, 68, 129, 130]. Decreased cmyc expression level, cell proliferation and in vivo tumor growth were consistently observed in almost
all of the cancer cell lines upon the knock-down of p90/CIP2A via siRNA. The fact that p90/CIP2A can
be expressed in premalignant stage and malignant stage indicated that p90/CIP2A may play essential
roles in cellular transformation and in cancer progression. In our study, the phenotypic analysis of
p90/CIP2A in lung cancer cell confirmed the results by showing the decreased cell proliferation,
clonogenic ability and anchorage-dependent cell growth along with the knock-down of p90/CIP2A.
Unfortunately, no systematic study has been performed to analyze the proteome change upon
the expression change of p90/CIP2A at the post-translational level. In this study, we implemented twodimensional electrophoresis-based proteomic approach to explore the global protein expression change
upon the loss of p90/CIP2A. With this method, we found that p90/CIP2A may participate in cell
metabolism, transcriptional and translational control and protein signaling pathways. In search of the
literature, it revealed that 30 out of the 47 proteins have been found to be associated with cancer.
Twenty-five percent of the altered proteins were associated with metabolism. The relationship between
metabolism and cancer was described long time ago after the discovery of cells undergoes glycolysis
instead of oxidative phosphorylation in proliferating and cancer cells. Recently, it was found that
metabolic-associated genes play active roles in cell transformation and tumorigenesis rather than bystander. Oncogenic factors like Ras, c-myc and HIF1 have been reported to be able to reprogram cellular
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metabolism pathways to favor the cancer cell growth [131]. C-myc is a oncogene that controls diverse
cellular pathways, including metabolism. It is therefore not surprising that p90/CIP2A could affect the
expression of metabolic enzymes like L-lactate dehydrodrenase via c-myc-dependent pathways [131].
The presence of the other c-myc-independent genes implied p90/CIP2A may regulate metabolic
pathway through other unknown mechanisms.
Aberrant transcription and translation have been reported in cancer [132]. Besides the
transcription factors, other factors in the transcription and translation machinery have also been found to
be altered in cancer, which can be triggered by abnormal activation of upstream biochemical pathways
[132]. Although the mechanism of how p90/CIP2A contributed to such alterations is still unknown, it
is speculated that p90/CIP2A may exert such effects by regulating the upstream biochemical pathways
like AKT. AKT is a central regulator which integrates different stimuli and then transmits the signal to
appropriate substrates through phosphorylation. Upon the stimulation of growth factors, AKT is able to
promote protein synthesis by regulating the phosphorylation of ribosomal protein p70 S6 kinase, and
eukaryotic initiation factor 4E binding protein. We also found that p90/CIP2A is able to regulate the
phosphorylation status of AKT, which may partially explain the resulted changes of transcription and
translation machinery from p90/CIP2A knock-down [133].
Deregulated pathways are common events in cancer progressions [134]. Key signaling
molecules will either be increased to promote tumor growth or down-regulated to reduce the constraint
of cell proliferation. In our study, we found several signaling molecules that were altered with the loss of
p90/CIP2A. We chose three of them for Western-blotting validation. 14-3-3 epsilon belongs to the 14-33 family which has the feature to bind to the phosphor-serine residue and regulate composition of
different protein complexes. Signaling molecules like TAK1 and protein phosphatase 2C beta (PPM1B)
in MAPK pathway can be regulated 14-3-3 epsilon [135]. Interestingly, molecules in the MAPK
pathway are also targets of PP2A. Therefore, p90/CIP2A may be able to modulate the activity of the
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MAPK pathway by directly targeting MAPK substrates or indirectly regulate through 14-3-3 epsilon.
Another interesting molecule altered by p90/CIP2A is the EBP1. EBP1 negatively regulates the
signaling pathway transduced by ErbB3 [136]. The observation that the expression of EBP1 was
increased upon the loss of p90/CIP2A raise the possibility that p90/CIP2A might be able to regulate the
down-stream signaling pathways through the regulation of EBP1.
Taking advantage of bioinformatic tool, we predicted four transcription factors that may
partially contribute to the expression change of the differentially expressed proteins. Although the direct
interaction network of p90/CIP2A with other known pathways was not detected in the prediction, we
were able to find several differentially expressed proteins that share common transcription factors such
as CREB, ESR-1, c-myc and ER-1. The presence of c-myc in the bioinformatic analysis ensures the
reliability of the prediction by this method. We chose to examine the phosphorylation of CREB based on
three reasons. First, CREB is a transcription factor that has been implicated in the development of lung
cancer. Second, CREB is a substrate of AKT, whose phosphorylation has been shown to be regulated by
p90/CIP2A in hepatocellular carcinoma. The third reason is that p90/CIP2A is mainly localized in the
cytoplasm while CREB is localized in nucleus. In this case, we hypothezed that p90/CIP2A may be able
to influence CREB phosphorylation by regulating the activity of upstream kinases. In fact, CREB can be
activated by multiple signaling pathways, including increased concentration of cAMP, membrane
depolarization and growth factors. Our study found that only the growth factor can induce the
phosphorylation change of CREB, but not KCl and forskolin. This indicated that p90/CIP2A is able to
enhance cell proliferation by post-translational regulation of AKT-CREB axis, which is c-myc
independent.
Although p90/CIP2A regulates the phosphorylation of CREB through AKT, the mechanism is
still unknown since CREB is mainly localized in the nucleus, the p90/CIP2A, localized in the
cytoplasma, seems to not be able to target CREB in a direct way. Therefore, this event may occur
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through the regulation of upstream kinases like AKT. Although previous studies showed p90/CIP2A can
target AKT, we report novel data that p90/CIP2A can regulate the phoshporylation of certain AKT
substrate.
In conclusion, our proteomic study not only extended our understanding of the role of
p90/CIP2A in lung cancer progression by modulating the expression of cell-related behavior, we also
found that p90/CIP2A can regulate certain AKT substrates. Follow-up studies may be performed to
identify the AKT substrates that can be recognized by p90/CIP2A, which will help us elucidating the
role of p90/CIP2A in AKT signaling network.
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Chapter 4: p90/CIP2A promote cancer cell proliferation by regulating glycolytic pathway

4.1

Introduction
Cancer results from uncontrolled cell proliferation, which requires high demands of energy

to fuel the cell growth and division. Glucose is the major source of energy production in normal and
cancer cells. In normal cells, glucose is processed by glycolysis to produce pyruvate in the cytosol,
which is subsequently converted to carbon dioxide in the mitochondria under aerobic condition.
However, glycolysis is favored under anaerobic condition, where the little pyruvate will be dispatched to
mitochondria for further processing. Otto Warburg was the first person to observe that cancer cells
preferred the use of glycolysis to generate energy in the presence of ample oxygen, which is known as
“Warburg effect” [77, 137]. Based on recent advances in the discovery of mutated metabolic genes in
cancer, the conception that metabolic pathways in cancer cell had been reprogrammed by activated
oncogenes and inactivated tumor suppressors to promote cell proliferation was proposed, and it is now
accepted as a hallmark of cancer [82, 138] . Although the glycolytic pathway had been well elucidated,
the oncogene regulating this process is still poorly understood.
p90/CIP2A (Cancerous inhibitor of PP2A), a recently characterized oncoprotein,

promotes

cell proliferation and tumor growth by stabilizing the oncogenic transcription factor, c-myc, at posttranslational level [62]. c-myc regulates the transcription of almost 15% of the human genome, and
promotes diverse cellular functions including cell proliferation, cell differentiation, cell cycle,
metabolism and apoptosis [57, 139]. The deregulated c-myc expression has been found in many
different types of cancer and is considered an essential gene for tumor progression. Under normal
circumstance, the transcriptional activity of c-myc is positively regulated through phosphorylation at
Serine 62 and negatively regulated by desphosphorylation of S62 by PP2A and phosphorylation of T58
by GSK3β [47]. The synergism of PP2A and GSK3β lead to the ubiquitin-dependent degradation of c78

myc[47]. Therefore, the role of p90/CIP2A in promoting c-myc stability can lead to increased cell
proliferation of c-myc. In contrast, the down-regulation of p90/CIP2A can greatly inhibit the cell
proliferation in many different cancer cell lines including, breast cancer cell line, prostate cancer cell
line and cervical cancer cell lines. However, whether this protein has any other function in regulating
cell proliferation is still unknown. Our previous studies using proteomic approach established that
several metabolic-associated enzymes, and glycolytic enzymes were altered when endogenous
p90/CIP2A was depleted. Given the function of p90/CIP2A in cell proliferation, we hypothesize that
p90/CIP2A may play important roles in the integrity of metabolic network in cancer cells.
Recently developed metabolomics is expected to facilitate the identification of the regulation.
Metabolomics can provide global qualitative and quantitative analysis of small-molecule metabolites by
investigating chemical processes involving the metabolites, and shows great promise as a means to
identify biomarkers of drug efficacy and understanding of metabolic mechanisms [140, 141]. The
adoption of high-throughput metabolite separation method, coupled with pattern recognition analysis,
could possibly explain whether the knock-down and over-expression of p90/CIP2A could affect cellular
metabolites. In addition, it may help identify what crucial biomarkers play an important role in the
evens. In the present study, metabolomics carrying cellular metabolites of H1299 cells were developed
to analyze changes of metabolites in the absence and over-expression of p90/CIP2A. First, we were
interested in identifying metabolites that, being specifically regulated in the absence and over-expression
of the protein, might be involved in cell proliferation.

Second, we wanted to exploit the metabolomics

data to identify, among the protein-regulated metabolites, metabolites capable of functionally regulating
cell proliferation, as p90/CIP2A does. Thus, providing reasonable mechanisms that described how
proteins promote the cell proliferation through metabolites. We hypothesize that the achievement of
the two objectives will provide new data that correlates cell proliferation with the interaction between
p90/CIP2A and metabolites.
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Here we present a comparative analysis of metabolic regulation in H1299 cells with overexpression of p90/CIP2A and without p90/CIP2A. We further identified the key altered levels of
metabolites as biomarkers and described their differential changes. At last, we report the use of crucial
metabolites that were down-regulated and up-regulated in H1299 cells with over-expression and loss of
p90/CIP2A, respectively, to regulate the proliferation.

These results may have significant implications,

not only in representing an example of the use of differential metabolomics approach to investigate the
interrelation of oncogene with metabolites, but as an indication of how this technology can be exploited
in the mechanisms of oncogenesis.
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4.2

Materials and methods

Metabolite extraction. Total metabolites were extracted as described previously with modifications
[142]. Briefly, cells were grown in 10-cm petri dish until they reach 80-90% confluence. After the
removal of growth media, cells were immediately washed three times with ice-cold phosphate buffered
saline (PBS) and quenched with 1ml 100% cold methanol (-20oC).

Cells were detached from petri dish

by cell scraper and collected in 2ml Eppendorf tubes. To lyse the cells, samples were sonicated three
times with 3W for 20s in ice using Sonicator 3000. Cell lysates were centrifuged at 16,000 x g for 15
mins at 4oC. Supernatants were collected into a new tube, and the cell pellets were extracted again with
another 500 ul cold methanol and processed as described above. After the centrifuge, the pellets were reextracted one more time with 500ul HPLC-grade water. The supernatants collected were combined,
dried in a room-temperature vacuum-speed centrifuge, and stored at -80oC for further experiment.
GC-MS analysis.

GC-MS analysis is carried out with a variation on the two-stage technique as

described previously [142].

In brief, samples were derivatized and then used to protect carbonyl

moieties through methoximation through a 90 min 37℃ reaction with 40 μL of 20 mg/mL
methoxyamine hydrochloride (Sigma-Aldrich) in pyridine. This was followed by derivatization of acidic
protons

through

a

30

min

37℃

reaction

with

trimethylsilyltrifluoroacetamide (MSTFA, Sigma-Aldrich).

an

addition

80

μL

N-methyl-N-

The derivatized sample of 1 μL was

injected into a 30m × 250 μm i.d. × 0.25 μm DBS-MS column using splitless injection, and analysis was
carried out by Trace DSQ II (Thermo Scientific, IL). The initial temperature of the GC oven was held at
85℃ for 5 min followed by an increase to 330℃ at a rate of 15℃ min-1 , then held for 5 min. Helium
was used as carrier gas and flow was kept constant at 1 mL min-1. The MS was operated in a range of
50-600 m/z.
Data processing.

Spectral deconvolution and calibration was performed using AMDIS and internal

standards. A retention time (RT) correction was performed for all the samples. Then the RT was used as
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reference. The remaining spectra were acquired and a file containing the abundant information of each
metabolite from all the samples was assembled. Metabolites from the GC-MS spectra were identified by
searching the National Institute of Standards and Technology (NIST) library, the NIST MS search 2.0.
The resulting data matrix was normalized using the concentrations of added internal standards. The sum
peak area was not used since it showed a positively significant correlation with the double increasing
BLFX concentrations. The resulting normalized peak intensities formed a single matrix, with Rt-m/z
pairs for each file in the dataset.

This file was then used for further statistical analysis.

Independent component analysis (ICA), is a popular data-driven blind source separation technique that
has been applied to a number of biological and medical applications [143]. In the analysis, the
generative linear mixing model, X = EC, is used, where X is the mixture that is factorized into a mixing
matrix E and independent source component C. It is able to add a further value for biological
interpretation, since it is an extension of covariance analysis by looking for kurtosis thresholds or high
entropy. To test for differences in the median concentrations of metabolites between experimental and
control groups, one-way analysis (ANOVA) was used. Differences were considered statistically
significant at p < 0.05.
Statistical analysis.

After the normalization, the standards were removed so that the data used for

modeling consisted of extracted compounds. Components that were identified as the same compound
were averaged. Metabolic data were presented as means ± SDs. Transformations and manipulations
were done using Excel.

Significance Analysis of Microarrays (SAM), and hierarchical clustering

(HCL) were performed with MeV 4.7.4. SAM was used to examine expression differences between
the double increasing BFLX concentrations by using a multi-class comparison, which consisted of seven
groups and 1.91 were used as δ cutoffs.

Orthogonal function partial least squares (O-PLS-DA) were

applied to the different variable scaling methods for comparison purposes (unit variance, Pareto and
centered scaling) using SIMCA 12.0. Potential markers of interest were extracted from the S-plots
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constructed after the analysis with OPLS-DA, since they showed statistically significant (P < 0.05)
difference in abundance, and were significantly elevated (p(corr)[1] > 0.85). Ingenuity network analysis
was performed with MetPA (http://metpa.metabolomics.ca./MetPA/faces/Home.jsp) based on database
source

including

the

KEGG

(http://www.genome.jp/kegg/),

Metabolic

Pathways

Database

(http://metacyc.org/), Escherichia coli K-12 (http://ecocyc.org/) to identify the affected metabolic
pathways analysis & visualization. The possible biological roles were evaluated by the enrichment
analysis using the MetaboAnalyst. T-test and correlation analysis were performed using Excel.
Hexokinase assay. Hexokinase assay was performed using the Hexokinase Assay Kit (Biomedical
Research Service Center, University of Buffalo, NY) according to manufacturer’s instructions. Briefly,
105-106 cells were washed twice with ice-cold PBS and lysed with 100µl 1X cell lysis solution. Cell
lysates were centrifuged in a refrigenerated microcentrifuge for 3 mins at maximal speed, collected and
stored on ice for kinase assay.
Kinase assay was initiated by adding 50µl HK working solution (20 µl HK substrate dissolved in 1 ml
HK assay solution) to 50 µl cell lysates in 96-well microplate (Corning, CA) and incubate at 37oC for 10
min or 20 mins. Reaction was stopped by adding 50 µl 3% acetic acid. Colometric absorbance was
measured with microplate reader at O.D. 492 nm (Thermo Scientific, IL). Kinase activity was measured
by a kinetic format and calculated according to the following equation:
Enzyme activity in Units/ml= (O.D. 20min – O.D. 10 min) X 110.
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4.3

Results

Effect of p90/CIP2A on characteristics of cellular metabolic response
To investigate the role of p90/CIP2A in cellular metabolism, GC/MS based metabolomics
approach was used to investigate differential metabolic responses to the absence and over-expression of
p90/CIP2A. Quantitative data was obtained for 97 metabolites from 176 peaks,

after the deletion of

seven peaks that were below the limit of quantitation or too unstable to yield reliable information (Fig.
15) . The 97 compounds were categorized into six metabolic pathways: amino acid metabolism (24),
carbon metabolism (30), fatty acid metabolism (18), oxidative phosphorylation (3), nuclear acid
metabolism (4) and unknown (18) (Fig. 16A) (Table. 10). The supervised OPLS model was used to
enhance biomarker discovery efforts. The OPLS-DA approach distributed the five sample groups into
three faces in a 3-D scatter plot. The control, plk0.1, 90.5, 90.2, and 90+ were located in the bottom face,
left and right faces, respectively (Fig. 16B). Thus, the OPLS-DA approach was applied to obtain better
discrimination between the control and experimental groups, based on the differences in their metabolic
profiles, and the experimental groups between the loss and overexpression of p90/CIP2A. The 97
compounds were shown in a clustered heat-map format. The format showed that 90.2 and 90.5 were
separately clustered together, and then p90+ was added (Fig. 16C). The three groups were closely
related to each other, compared with two controls, wide type cell (WT) and plk0.1, which were clustered
together. These results showed that the metabolic profiles had significantly adjusted as a result of
p90/CIP2A absence or over-expression.

84

Figure 15. Metabolic profiling by GC/MS. It shows the capacity to resolve 79 compounds within 50
mins run. GC/MS chromatogram of the total metabolites extracted from H1299 lung cancer cell lines.
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A.

Carbon metabolism
Fatty acid metabolism
Oxidative phosphorylation

Amino acid metabolism
Nuclear acid metabolism
Unknow

19%
30%
3%
4%

19%
25%

B.
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C.

Figure 16. Profile of metabolic regulation to cells with the loss and over-expression of p90/CIP2A.
A, The whole cellular spectrum proﬁle based on metabolic pathways. B, OPLS-DA results for control
and experimental groups. Significant metabolomic difference was shown between them in 3-D plot. One
data point stands for one subject. C, Hierarchical clustering analysis of metabolite concentrations in cells
with the loss and over-expression of p90/CIP2A.

Identiﬁed metabolites were analyzed for any

apparent patterns. Clustering was performed using Pearson correlation as the distance metric. Cluster
tree shows how the samples and metabolites divide. Across the bottom are the metabolites, and along the
side are the samples.
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Table 10. Complete list of identified metabolites by GC/MS by comparing to the commercial NIST
library.
Retention time

Metabolite

6.74

Propanoic acid

6.96

L-Alanine

7.67

l-Alanine

8.27

Glycine

8.77

Ethanedioic acid

9.48

Trisiloxane

9.68

(R)-(-)-2-Pyrrolidinemethanol

9.76

Phosphoric acid

10.05

Isoborneol

10.17

Glycine

10.27

Glyoxylic acid, di-TMS

10.67

2-Dimethyl(trimethylsilyl)silyloxytridecane

10.82

L-Norvaline

11.59

Phosphonic acid

12.37

Silanol, trimethyl-, phosphate

13.03

L-Isoleucine

13.08

L-Proline

13.29

Glycine

13.45

4-Piperidinone

13.85

Bis(trimethylsilyl)3,4-dimethylphenylphosphonate

14.38

L-Proline

14.79

Silanamine

14.88

L-Serine

15.51

Cobalt

15.62

N,O,O-Tris(trimethylsilyl)-L-threonine

15.94

Glycine

16.17

Glucopyranoside

16.27

Arabino-Hexos-2-ulose

16.43

Glycine
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16.48

Glycine

16.68

Alanine

16.8

Benzene

17.36

Glycine

17.48

Hexadecane

17.72

Ethanamine

17.78

L-Aspartic acid

17.96

Trimethylsiloxy(trimethylsilyl)proline

18.19

Malic acid

18.61

Silane

18.89

L-Proline

19.1

L-Proline

19.42

Cyclohexanecarboxylic acid

19.68

2,3,4-Trihydroxybutyric acid tetrakis(trimethylsilyl)
deriv.

19.9

Cystathionine

20.29

L-Proline

20.46

Pentanedioic acid

20.77

Citrulline

20.87

Silanamine

21.38

Glutamine

21.65

(Z,Z)-3-Methyl-3H-cyclonona(def)biphenylene

21.74

Octadecane

22.04

2-Hydroxybenzylamine

22.15

Propanoic acid

22.34

Succinic acid

23.23

Tetradecane

23.34

Heptadecane

24.04

1,4-Butanediamine

24.17

DL-Arabinopyranose

24.4

Butanoic acid

24.43

Phosphoric acid

24.72

Phosphoric acid

24.84

Uridine
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25.01

N Acetyl aspartic TMS

25.07

Phosphoric acid

25.48

Ethanol

25.66

Propanoic acid

25.76

1,2,3-Propanetricarboxylic acid

26.12

d-Erythrotetrofuranose

26.4

2-Pentenedioic acid

26.54

Tetradecanoic acid

27.02

D-Fructose

27.52

d-Glucose

27.87

d-Glucose

28.04

Dodecanoic acid

28.29

D-Mannitol

28.54

n-Pentadecanoic

28.8

Phosphonic acid

29.36

Pantothenic acid

29.8

D-Glucopyranoside

29.95

2(1H)-Pyrimidinone

30.03

Palmitelaidic acid

30.1

Inositol

30.22

D-Mannopyranoside

30.48

Hexadecanoic acid

31.3

Myo-Inositol

31.63

Myo-Inositol

31.88

1,3-Dioxolane

31.99

Cyclopropanetetradecanoic acid

32.3

Heptadecanoic acid

32.54

D-Glucopyranoside

32.64

Butane-1,3-dione

32.9

Butanoic acid

33.5

D-, 2,3,4,6-tetrakis-O-(trimethylsilyl)-

33.57

11-cis-Octadecenoic acid

33.71

11-cis-Octadecenoic acid
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34.1

Octadecanoic acid

34.2

16-Trimethylsilyloxy-9-octadecenoic acid

35.16

D-Galactofuranose

35.34

d-Glucose

35.58

Octadecane, 3-ethyl-5-(2-ethylbutyl)-

36.61

D-Xylopyranose

36.87

Myo-Inositol

38.82

1,2-Benzenedicarboxylic acid

38.98

Octadecane

39.64

Glucuronolactone

39.74

Hexadecanoic acid

40.4

Uridine

40.47

D-Glucopyranoside

40.49

1,3-Dipalmitin trimethylsilyl ether

40.95

D-Xylopyranose

41.93

D-Turanose

42.09

D-Glucopyranoside

42.25

1-Monooleoylglycerol trimethylsilyl ether

42.5

D-Glucopyranoside

43.15

2(1H)-Pyrimidinone

43.45

2,4-Imidazolidinedione

43.82

2(1H)-Pyrimidinone

45.23

D-Glucopyranoside

46.2

D-Ribofuranose

46.34

2(1H)-Pyrimidinone

46.54

5'-Adenylic acid

47.54

Cholesterol trimethylsilyl ether

47.7

D-Galactopyranoside

48.92

Stearic acid
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Identification of sample recognition using independent component analysis (ICA)
To determining the characteristic metabolites in cells with absence and over-expression of
p90/CIP2A, the multi-class unpaired method of SAM was used to identify the metabolites whose
concentration differed significantly among all samples collected.

SAM analyses were able to

differentiate the difference. SAM (for a delta value of 1.91% and 0% false discovery rate (FDR)—
median) identified 38, 50, 61, 70, 71, 73 peaks representing 30, 42, 48, 53, 54, 56 metabolites in BLFXcon64, BLFX-con32, BLFX-con16, BLFX-con8, BLFX-con4 and BLFX-2, respectively (Fig. 16).

The

56 positively signiﬁcant metabolites from 73 peaks detected in BLFX-2 contained all changes occurred
in the other samples. These were listed in order by decreasing signiﬁcance: tetradecanoic acid,
palmitelaidic acid, phosphoric acid, glycine, 9H-Pyrido[3,4-b] indole and Morphinan as the first six
metabolites (Fig.17A-C,). According to the parametric t-test, we found that the majority of the altered
metabolites were increased with the double increasing BLFX concentrations.

Then, ICA was separately used to identify significant differences in the data set.

ICA is one of

the unsupervised algorithms that can extract higher-order statistical structures, from which extracted
transformation vectors are able to indicate the occurrence of specific metabolites. It provides similar
relative metabolite level responses for different processes, due to a time-lag effect or analogous
biochemical regulation. In the present study, ICA of the metabolites gave complete separation of sample
groups (Fig. 18A). The extracted transformation vectors IC1–IC2 revealed information for biomarker
identification. First, the three experimental groups (90.5, 90.2 and 90+) and the two controls (control and
plk) are separated on IC1. The second component (IC2) depicts p90/CIP2A and vector roles in the five
groups (Fig.18A). Thus, the role of p90/CIP2A was completely resolved by combining the distinct
features of metabolite data.
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Figure 17. Histogram of significant different metabolites by SAM analysis.

SAM analysis was

used to differentiate the metabolites which are significantly altered in decreased or increased of
p90/CIP2A expression.
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A.

B.
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Figure 18. ICA for cells with the loss and over-expression of p90/CIP2A.

A, Sample pattern

recognition in a metabolite covariance matrix, showing visualization of independent components 1 and 2
(IC1 and IC2). For each experiment three independent biological replicates were measured. The control
and plk0.1 were used as controls of 90+, and 90.2 and 90.5, respectively. The following biological
information was extracted from the plots: (a) IC1 separates two controls and three experimental groups;
(b) IC2 separates the respective two comparison: control vs 90+ and 90+ vs 90.2 and 90.5. B, clustering
of the ICA loadings (weights) on IC1–IC2. The loadings are proportional to the importance or
significance of a metabolite for a corresponding independent component. The biclustering diagram was
constructed from the first 20 ranked loadings for the corresponding IC1 and IC2. C-E, Plots of identified
biomarkers for combination of IC2 and IC1. Biomarkers were identified from metabolites with high
absolute weights of IC2 and low absolute weights of IC1. Glucose (C), glycine (D) and proline (E) were
identified.
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Identification of biomarkers based on metabolites of ICA
A ranked assignment of metabolite sets involved in the observed phenomena is able to be
characterized based on the biological interpretation of the transformation vectors IC1-IC2, and the new
independent components IC1 and IC2. The assignment is visualized in a biclustering diagram, which
displays the loading of different independent components IC1 and IC2. The loading coefficients
represent the relative degree of each component on the observed sample discrimination along the
transformation vectors, and are directly related to their importance on this biological phenomenon. It is
reasonable that crucial biomarkers are identified based on their different response effects to IC1 and IC2.
Two control groups (WT and plk0.1) and three test groups (90+, 90.2 and 90.5) are clearly divided by
IC1, while the samples with over-expressed p90/CIP2A (90+) and without p90/CIP2A (90.2 and 90.5)
are highly related to IC2. Compared with IC1, IC2 include the following key differential metabolites:
glucose, propanoic acid, L-proline, 1, 2, 3-propanetricarboxylic acid, myo-inositol, cholesterol. They
have distinct difference on loading with IC1. There were two types of changes for the six metabolites:
(i), The opposite regulations are detected between the loss and over-expression of p90/CIP2A compared
with their respective controls, including glucose, cholesterol and 1, 2, 3-propanetricarboxylic acid. (ii)
The same change trend was determined in the three tested groups, and was compared their
corresponding controls, including propanoic acid, L-proline and myo-inositol. Thus, biological
significance of glucose, cholesterol and 1, 2, 3-propanetricarboxylic acid was related to p90/CIP2A, and
changes of propanoic acid, L-proline and myo-inositol vector was associated with the vector. The
biological significance was different between the three metabolites, indicating that p90/CIP2A promotes
the use of glucose and limits the use of cholesterol and 1, 2, 3-propanetricarboxylic acid. In summary,
glucose, cholesterol and 1, 2, 3-propanetricarboxylic acid are three crucial biomarkers that differentiate
between over-expression of p90 from the loss of p90 (Fig. 18B).
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p90/CIP2A regulates glucose metabolism through hexokinase
Since the depletion of p90/CIP2A can increase the intracellular concentration of glucose, the
utilization of glucose may be impaired in p90/CIP2A deficient cells. To confirm that, we quantified the
glucose concentration at different time points in H1299 cell line (Fig. 19A). Interestingly, there was no
significant difference of glucose concentration observed between wild type (WT) cell line and
p90/CIP2A deficient cell line, which implied that p90/CIP2A does not influence the uptake of glucose
(Fig. 19A). However, glucose concentration was increased to 1.2 fold in comparision to the wild type
cell line (Fig. 19A) indicating the role of p90/CIP2A in the metabolic process of glucose. Hexokinase is
the first enzyme to break down glucose and is subjected to the regulation of AKT. Our previous results
showed that p90/CIP2A can regulate the phosphorylation of AKT in response to growth factors.
Therefore, hexokinase may be affected by the loss of p90/CIP2A. As expected, the knock-down of
p90/CIP2A in both of H1299 and H838 cells decreased the hexokinase activity (Fig. 19B). In contrast,
overexpression of p90/CIP2A in H460 cells increases hexokinase activity to 123% compared to control
cells.
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A.

B.
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Figure 19. p90/CIP2A regulates glucose metabolism through hexokinase. (A) Quantification of
intracellular concentration of glucose in H1299 cells. 7X105 cells (H1299 shRNA control or p90/CIP2A)
were seeded in 6-well plates with triplicate for 24 hrs. After incubation, cells were washed five times
with glucose-free RPMI medium and incubated in glucose-free medium for 30mins to deplete the
intracellular glucose. Complete growth medium was then added and cells were collected at different
time points as indicated by direct lysis in RIPA buffer. Cells were centrifuged to remove the cell debris
and supernants were collected for glucose quantification or for Western-blot of normalization using
actin (Upper panel). Fold of glucose concentration change was normalized to control. (Lower panel) (C)
Hexokinase activity was measured based on the reduction of the tetrazolium salt INT in a NADHcoupled reaction to INT-formazan, which is read at OD492 nm. Kinase activity was normalized to actin
level.
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4.4

Discussion
The reprogramming of metabolic pathways to fuel cell growth by cancer cell has been

considered one of the hallmarks of cancer [85]. Both of the activated oncogenes and inactivated tumor
suppressors are contributing to these alterations during cellular transformation [79]. Oncoproteins like cmyc, hypoxia-induced factor 1 (HIF1), and K-ras have been proved to be important molecules to
regulate metabolism [79]. However, how these proteins contribute to cancer-associated metabolism is
still poorly understood. In this study, we use global metabolic profiling to study the function of a novel
oncoprotein p90/CIP2A in cancer metabolism.
We identified three metabolites that were significantly altered correspondingly with the change
of p90/CIP2A level (both in knock-down and overexpression): glucose, cholesterol and 1,2,3propanetricarboxylic acid. Of interest, glucose and 1,2,3-propanetricarboxylic acid are associated with
glycolysis and Kreb cycle pathways. The knock-down of p90/CIP2A increased the intracellular glucose
concentration, while the overexpression of p90/CIP2A enhanced the glucose consumption. These results
implied that p90/CIP2A may positively regulate the glucose metabolism. Hexokinase is the first enzyme
in the glycolytic pathway to phosphorylate glucose to produce glucose-6-phosphate. The activity of this
enzyme is subjected to the regulation of AKT [92, 95, 144]. Interestingly, studies performed by our
group and others had showed that p90/CIP2A is able to regulate phosphorylation status of AKT in
response to growth factor stimulation and cellular stress. Therefore, the role of p90/CIP2A in promoting
cell proliferation may be partially through the regulation of EGF-PI3K-AKT pathway.
Kreb cycle (tricarboxylic acid cycle, TCA cycle) is another pathway which is usually used by normal
cells to generate energy. Although the defects of TCA cycle has been reported to be associated with
cancer, the molecular mechanism linking TCA cycle defects to cancer remained to be defined [145,
146]. Mutations of the enzymes of TCA cycle like isocitrate dehydrogenase, succinate dehydrogenase
and fumarate hydrogenase had been found in different solid tumors [147]. These mutated enzymes will
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have recessive or dominant functions and produce metabolites that repress cell differentiation.
However, whether there is any other factor besides mutations that interrupt normal TCA cycle in cancer,
is still poorly defined. Aconitase is an enzyme in the TCA cycle that converts citrate into iso-citrate
[148, 149]. Abnormal activity of aconitase has been reported in prostate cancer, which leads to high
levels of citrate. The ratio of citrate to isocitrate has been considered as a marker for tumor grade
differentiation [150]. However, how the activity of the aconitase is regulated in cancer is poorly
understood. In our results, we find that metabolite 1,2,3-propanetricarboxylic acid, an inhibitor of
aconitase, is decreased along with the overexpression of p90/CIP2A. This implied that p90/CIP2A may
employ an indirect way to promote the TCA cycle in cancer cells, which leads to the cell proliferation.
Taken together, our studies showed that p90/CIP2A can promote cell proliferation by regulating
metabolic pathway in cancer cells. It achieves this not only through c-myc dependent pathway, but also
through a c-myc-independent pathway with the regulation of the molecules critical for glycolysis and
TCA cycle. Our results expanded the understanding of the p90/CIP2A in cancer cell growth. Also, it
provided an important example for the use of metabolomics in the study oncogene of function in cancer
field.
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Chapter 5: Final conclusions and future directions
5.1.

Overview and final conclusions
Tremendous work had been done in the past decades to elucidate the molecular

mechanism of oncogenesis. The inhibition of PP2A has been considered an important event for the onset
of tumor formation. Therefore, the identification of factors that contribute to this inhibitory effect are of
great importance. p90/CIP2A is such a protein whose function was unknown until recently. The
importance of this protein in cancer has been considered valuable and an increasing number of
researchers have started studying its study the biological function. Yet, little process had been made, and
the physiological function of p90/CIP2A is still unknown.
In this present study, we mainly applied “-omic” approach to explore the biological function
of p90/CIP2A in cancer cell behavior, especially cell proliferation. On the second chapter, we found that
p90/CIP2A can regulate the phosphorylation of JNK-c-Jun pathway by using phosphoproteomic array.
JNK-c-Jun is an important component of the MAPK kinase pathway, which has opposite functions in
cancer by either promoting cell proliferation or initiating apoptosis. This is dependent on the
extracellular stimuli. In response to the EGF treatment, p90/CIP2A can increase the phosphorylation of
JNK and its substrate c-Jun and ATF2, which implied a possible target of p90/CIP2A. This regulation
was not observed before.
On the third chapter, we used proteomic approach to investigate the proteome change upon
the loss of p90/CIP2A. By utilizing advanced bioinformatic tools, we established that p90/CIP2A can
regulate the phosphorylation of CREB indirectly, which is done through AKT pathway. AKT is a central
regulator of cell proliferation, cell growth and cell survival by integrating distinct upstream pathways,
which in turn phosphorylate downstream targets. Although AKT has been reported to be a target of
p90/CIP2A, the downstream effects had not been reported. In our study, we found that p90/CIP2A can
prime the AKT for the phosphorylation of CREB, which may be a way for p90/CIP2A to promote cell
proliferation.
On the fourth chapter, we described the metabolomic analysis of the loss or overexpression of
p90/CIP2A. The recent proposed idea that cancer is also a metabolic diseases extends our understanding
102

of the underlying mechanism of cell proliferation and cancer cell growth. Our proteomic data suggested
that p90/CIP2A can alter the expression levels of several metabolic enzymes, and may be a potential
oncogene to regulate cancer metabolism. Interestingly, we found that D-glucose is one of the most
significant metabolites during the loss or overexpression of p90/CIP2A. Further experiments also
showed the correlation between the hexokinase activity and p90/CIP2A expression level. This study
contributed to the cancer research field by understanding that p90/CIP2A can regulate cell proliferation
through the glycolytic pathway, and by demonstrating that metabolomic can be a useful tool to
investigate oncogene functions.
Taken together, we found that p90/CIP2A can regulate the JNK-c-Jun pathway, CREB
phosphorylation and glycolytic pathway (Fig. 20) .
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Fig. 20. Proposed model and research implications. (A) Upon the stimulation of growth factors,
receptor tyrosine kinase (RTK) localized in the receptor recruits the adaptor proteins CrkII, CrkL, Shc
and Grb2, which activate HPK1 kinase. The activation of HPK1 kinase can lead to the phosphorylation
of several MAPKKK kinase like (MEKK1/4 and MLK2/3), which results in the activation of JNK
kinase via the activation of MKK4/7. Activated JNK can phosphorylate the transcription factor c-Jun
and ATF2, which initiate the transcription of cell proliferation genes. There are several molecules in this
process that can be negatively regulated by PP2A including TAK1, MEKK1/4, ASK1, MKK4/7 and
JNKs. Therefore, p90/CIP2A may have one or more targets for the regulation of this pathway. Future
studies can be focused to elucidate the mechanism by identifying p90/CIP2A target(s). (B) As described
previously, the activation of RTK, adaptor proteins (Gab1, Gab2 and IRS1) will be recruited by RTK
which results in the membrane localization of PI3K which phosphorylate PIP3 or activate PDK-1. Both
of these molecules will be able to activate AKT phosphorylation. AKT can phosphorylate the CREB,
which is localized in the nucleus and can promote gene transcription. In addition, AKT can
phosphorylate hexokinase II (HKII) and thus increase hexokinase activity to initiate glycolytic pathway.
In addition, AKT can also promote the localization of HKII to the outer membrane of mitochondria
where it forms complex with voltage-dependent channel (VADC). The resulted formation of this
complex will shied the cell from oxidative stress-induced apoptosis. Although previous results had
shown p90/CIP2A decrease the AKT-associated PP2A phosphatase activity, we have established that
p90/CIP2A can regulate the AKT substrate to favor cell proliferation in cancer cells.
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5.2

Future directions
Although we have determined that p90/CIP2A can alter the phosphorylation of JNK-c-Jun

pathway, the targets in this pathway are still unknown. Since several upstream molecules of JNK are the
target of PP2A, further work may be done to examine the phosphorylation of ASK1 and MEK1. This
will allow us to know how p90/CIP2A can regulate this stress response pathway.
In addition, we found two AKT substrates: CREB and hexokinase are subjected to the
regulation of p90/CIP2A. This data implied that p90/CIP2A may influence the AKT substrate
selectivity. To further understand the interrelation between p90/CIP2A and AKT, further work can be
done to identify those substrates. This will have two benefits: first, we will know which AKT-regulated
pathway can be targeted by p90/CIP2A. Second, by aligning the targets AKT substrate, we may find
consensus sequence recognized by p90/CIP2A, which may provide rationale for the drug design.
Although hexokinase may be a target of p90/CIP2A, we still don’t know whether p90/CIP2A
can confer cancer cell resistance to oxidative stress. Therefore, in future work, we can compare the
sensitivity of cells to oxidative stress by depletion of p90/CIP2A or overexpression of p90/CIP2A.
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Appendix
List of abbreviations

NSCLC

Non-small cell lung cancer

SCLC

Small cell lung cancer

EGF

Epidermal growth factor

EGFR

Epidermal growth factor receptor

PP2A

Protein phosphatase 2A

CREB

cAMP-responsive element

JNK

c-Jun N-terminal kinase

MAPK

Mitogen-activated protein kinase

PI3K

Phosphoinositide 3-kinase

SDS-PAGE

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis

2D gel

Two-dimensional electrophoresis

mTOR

Mammalian target of Rapamycin

GC/MS

Gas-chromatography mass spectrometry

shRNA

Short hairpin RNA

WT

Wild type

TCA cycle

Tricarboxylic acid cycle

DMEM

Dulbecco’s modified Eagle’s medium

RPMI1640

Roswell Park institute medium 1640

HRP

Horseradish-peroxidase

IHC

immunohistochemistry

DAB

3,3'-diaminobenzidine

ICA

Independent component analysis

SAM

Significant analysis of microarray

OD

Optical density
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